How many Aflibercept clinical trials are there?

456 Aflibercept clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 28 are actively recruiting participants. 286 are marked completed.

Are Aflibercept clinical trials recruiting in 2026?

Yes — 28 Aflibercept trials are actively recruiting in 2026, with 382 U.S. sites across 38 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Aflibercept being studied for?

Aflibercept is being studied for Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Macular Degeneration, Wet Macular Degeneration, Age Related Macular Degeneration and 301 more. The trials are grouped by indication on this page.

What phase is Aflibercept in?

Aflibercept clinical trials span 93 Phase 4, 99 Phase 3, 103 Phase 2, 33 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Aflibercept clinical trials?

The lead sponsor across the most Aflibercept trials is Bayer, with 217 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Aflibercept Clinical Trials (2026): 456 Studies for Diabetic Macular Edema & Neovascular Age-related Macular Degeneration

Creator: Hipa.ai Research
Published: 2026-05-14T21:39:10.694Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

456 Aflibercept clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 151 indications (including Diabetic Macular Edema & Neovascular Age-related Macular Degeneration) and 949,155 total planned enrollment. 99 Phase 3 Aflibercept trials and 103 Phase 2, 93 Phase 4 are listed. 38 Aflibercept clinical trials are actively recruiting at 382 U.S. sites across 38 states. Most recent activity: NCT07317934 (Jun 2032).

Where to Participate: All Aflibercept Trial Sites in the U.S. (382 sites across 38 states)

Every actively recruiting Aflibercepttrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AZ	Associated Retina Consultans	Gilbert85297	NCT07449923	Map
AZ	Adverum Clinical Site 126	Phoenix85014	NCT07482176	Map
AZ	Adverum Clinical Site 178	Phoenix85020	NCT07482176	Map
AZ	Adverum Clinical Site 223	Phoenix85020	NCT07482176	Map
AZ	Associated Retina Consultants - Phoenix	Phoenix85020	NCT07449923	Map
AZ	Barnet Delaney Perkins Eye Center	Phoenix85016	NCT05197270	Map
AZ	Barnet Dulaney Eye Center-Phoenix /ID# 256340	Phoenix85016	NCT05407636	Map
AZ	Phoenix Retina Clinical Trials, LLC - North Phoenix	Phoenix85050	NCT07449923	Map
AZ	Retinal Research Institute /ID# 256238	Phoenix85053	NCT05407636	Map
AZ	Adverum Clinical Site 229	Scottsdale85255	NCT07482176	Map
AZ	Research Network Arizona	Scottsdale85255	NCT07064759	Map
AZ	Retina Macula Institute of Arizona	Scottsdale85255	NCT07449923	Map
AZ	Retina Macula Institute of Arizona /ID# 271026	Scottsdale85255-4134	NCT05407636	Map
AZ	Scottsdale, Arizona	Scottsdale85255	NCT07205887	Map
AZ	Scottsdale, AZ	Scottsdale85255	NCT07205887	Map
AZ	Barnet Dulaney Perkins Eye Center	Sun City85351	NCT07064759	Map
AZ	Retina Associates	Tucson85704	NCT07064759	Map
AR	Adverum Clinical Site 198	Springdale72764	NCT07482176	Map
AR	Retina Partners of Northwest Arkansas, PLLC	Springdale72764	NCT07440225	Map
CA	Adverum Clinical Site 109	Bakersfield93309	NCT07482176	Map
CA	California Retina Consultants	Bakersfield93309	NCT07449936	Map
CA	California Retina Consultants - Bakersfield /ID# 256240	Bakersfield93309-1677	NCT05407636	Map
CA	Adverum Clinical Site 100	Beverly Hills90211	NCT07482176	Map
CA	Retina Vitreous Assoc Med Grp /ID# 256246	Beverly Hills90211	NCT05407636	Map
CA	Retina Vitreous Associates Medical Group	Beverly Hills90211	NCT07449923	Map
CA	Adverum Clinical Site 201	Campbell95008	NCT07482176	Map
CA	Retinal Diagnostic Center	Campbell95008	NCT07064759	Map
CA	Retinal Diagnostic Center /ID# 256262	Campbell95008	NCT05407636	Map
CA	Adverum Clinical Site 172	Encino91436	NCT07482176	Map
CA	The Retina Partners	Encino91436	NCT07449936	Map
CA	The Retina Partners - Encino /ID# 259660	Encino91436	NCT05407636	Map
CA	Adverum Clinical Site 169	Fullerton92835	NCT07482176	Map
CA	Retina Consultants of Orange County	Fullerton92835	NCT06662994	Map
CA	Retina Consultants of Orange County	Fullerton92835	NCT07064759	Map
CA	Retina Consultants of Orange County	Fullerton92835	NCT07449923	Map
CA	Glendale, CA	Glendale91204	NCT07205887	Map
CA	Glendale, California	Glendale91204	NCT07205887	Map
CA	Global Research Management, Inc.	Glendale91204	NCT07440225	Map
CA	Global Research Management, Inc.	Glendale91204	NCT07449936	Map
CA	Adverum Clinical Site 224	Huntington Beach92647	NCT07482176	Map
CA	South Coast Retina Center	Long Beach90807	NCT07449923	Map
CA	The Angeles Clinic and Research Institute	Los Angeles90025	NCT06121180	Map
CA	Modesto, California	Modesto95356	NCT07205887	Map
CA	Retinal Consultants Medical Group - Modesto	Modesto95356	NCT07449923	Map
CA	Retinal Consultants Medical Group (Site 024)	Modesto95356	NCT07440225	Map
CA	Mountain View, California	Mountain View94040	NCT07205887	Map
CA	Northern California Retina Vitreous Associates	Mountain View94040	NCT07064759	Map
CA	Northern California Retina Vitreous Associates Medical Group INC.	Mountain View94040	NCT07449936	Map
CA	Northern California Retina Vitreous Associates Medical Group, Inc.	Mountain View94040	NCT07496567	Map
CA	Kaiser Permanente	Oakland94611	NCT07449923	Map
CA	California Retina Consultants	Oxnard93036	NCT05197270	Map
CA	California Retina Consultants - Oxnard - North Ventura Road /ID# 262883	Oxnard93036	NCT05407636	Map
CA	Byers Eye Institute Stanford /ID# 262853	Palo Alto94303	NCT05407636	Map
CA	Retina Consultants of San Diego	Poway92064	NCT07449936	Map
CA	Adverum Clinical Site 215	Redlands92374	NCT07482176	Map
CA	California Eye Specialists Medical Group, Inc.	Redlands92373	NCT07449936	Map
CA	Retina Consultants of Southern California	Redlands92374	NCT07449923	Map
CA	Retina Consultants of Southern California (Site 043)	Redlands92374	NCT07440225	Map
CA	Kaiser Permanente - Riverside Medical Center /ID# 262413	Riverside92505	NCT05407636	Map
CA	Adverum Clinical Site 140	Sacramento95825	NCT07482176	Map
CA	Adverum Clinical Site 212	Sacramento95841	NCT07482176	Map
CA	Retinal Consultants Medical Group	Sacramento95841	NCT05197270	Map
CA	Retinal Consultants Medical Group	Sacramento95841	NCT07064759	Map
CA	Retinal Consultants Medical Group	Sacramento95841	NCT07449936	Map
CA	Retinal Consultants Medical Group - Parkcenter Drive	Sacramento95825	NCT07449936	Map
CA	Retinal Consultants Medical Group (Site 020)	Sacramento95825	NCT07440225	Map
CA	Retinal Consultants Medical Group (Site 022)	Sacramento95841	NCT07440225	Map
CA	Retinal Consultants Medical Group Inc.	Sacramento95825	NCT07064759	Map
CA	Sacramento, CA	Sacramento95825	NCT07205887	Map
CA	Sacramento, California	Sacramento95841	NCT07205887	Map
CA	Sactamento, California	Sacramento95825	NCT07205887	Map
CA	West Coast Retina Medical Group	San Francisco94109	NCT07064759	Map
CA	Orange County Retina Medical Group /ID# 256286	Santa Ana92705	NCT05407636	Map
CA	Santa Ana, California	Santa Ana92705	NCT07205887	Map
CA	Adverum Clinical Site 202	Torrance90503	NCT07482176	Map
CA	Macula Retina Vitreous Center - Torrance /ID# 270247	Torrance90503	NCT05407636	Map
CA	Adverum Clinical Site 189	Walnut Creek94598	NCT07482176	Map
CA	Bay Area Retina Associates	Walnut Creek94598	NCT07064759	Map
CA	Bay Area Retina Associates	Walnut Creek94598	NCT07449923	Map
CA	Bay Area Retina Associates - Walnut Creek - Lennon Lane /ID# 268513	Walnut Creek94598	NCT05407636	Map
CO	Retina Specialists of Colorado - Arvada	Arvada80002	NCT07449923	Map
CO	Retina Consultants of Southern Colorado	Colorado Springs80909	NCT07449936	Map
CO	Retina Consultants of Southern Colorado /ID# 256285	Colorado Springs80909	NCT05407636	Map
CO	Retina Consultants of Southern Colorado P.C.	Colorado Springs80909	NCT07064759	Map
CO	Adverum Clinical Site 116	Denver80207	NCT07482176	Map
CO	Southwest Retina Consultants	Durango81303	NCT07064759	Map
CO	Colorado Retina Associates	Lakewood80288	NCT05197270	Map
CO	Colorado Retina Associates	Lakewood80228	NCT07449936	Map
CO	Advanced Vision Research Institute /ID# 256380	Longmont80503	NCT05407636	Map
CT	Connecticut Eye Consultants, P.C.	Danbury06810	NCT07449923	Map
CT	Coastal Eye Surgeons, LLC	Greenwich06830	NCT07449923	Map
CT	CBCC Global Research Site:005	Manchester06042	NCT06132035	Map
CT	Retina Consultants, P.C. /ID# 273610	Manchester06042-3556	NCT05407636	Map
CT	Adverum Clinical Site 165	Waterford06385	NCT07482176	Map
CT	Retina Group of New England, PC	Waterford06385	NCT07449923	Map
FL	Advance Medical Research Group, Inc	Deerfield Beach33064	NCT07449936	Map
FL	Adverum Clinical Site 124	Deerfield Beach33064	NCT07482176	Map
FL	Adverum Clinical Site 184	Deerfield Beach33064	NCT07482176	Map
FL	CBCC Global Research Site:006	Deerfield Beach33064	NCT06132035	Map
FL	Adverum Clinical Site 176	Fort Lauderdale33308	NCT07482176	Map
FL	Fort Lauderdale, FL	Fort Lauderdale33308	NCT07205887	Map
FL	Fort Lauderdale, Florida	Fort Lauderdale33308	NCT07205887	Map
FL	Retina Group of Florida - Fort Lauderdale	Fort Lauderdale33308	NCT07449923	Map
FL	Retina Group of Florida (Site 070)	Fort Lauderdale33308	NCT07440225	Map
FL	Adverum Clinical Site 221	Fort Myers33912	NCT07482176	Map
FL	Vitreo Retinal Associates	Gainesville32607	NCT05197270	Map
FL	ClearVista Clinical Research	Hudson34667	NCT07064759	Map
FL	Adverum Clinical Site 214	Lakeland33805	NCT07482176	Map
FL	Florida Retina Consultants /ID# 256321	Lakeland33805	NCT05407636	Map
FL	Florida Eye Associates	Melbourne32901	NCT05197270	Map
FL	Adverum Clinical Site 213	Orlando32806	NCT07482176	Map
FL	Florida Retina Institute	Orlando32806	NCT07064759	Map
FL	Florida Retina Institute - Orlando /ID# 256373	Orlando32806-1101	NCT05407636	Map
FL	Retina Specialty Institute	Pensacola32503	NCT07064759	Map
FL	Retina Specialty Institute	Pensacola32503	NCT07449923	Map
FL	Retina Specialty Institute /ID# 256268	Pensacola32503	NCT05407636	Map
FL	Retinal Specialty Institute	Pensacola32503	NCT05197270	Map
FL	Eye Associates of Pinellas	Pinellas Park33782	NCT07449936	Map
FL	Fort Lauderdale Eye Institute	Plantation33324	NCT07449923	Map
FL	Fort Lauderdale Eye Institute (Site 042)	Plantation33324	NCT07440225	Map
FL	Adverum Clinical Site 183	South Miami33143	NCT07482176	Map
FL	MedEye Associates	South Miami33143	NCT07449923	Map
FL	Retina Vitreous Associates of Florida	St. Petersburg33711	NCT07064759	Map
FL	Retina Vitreous Associates of Florida - Saint Petersburg	St. Petersburg33711	NCT07449923	Map
FL	Retina Vitreous Associates of Florida - Saint Petersburg	St. Petersburg33711	NCT07449936	Map
FL	Retina Vitreous Associates of Florida - St. Petersburg /ID# 256279	St. Petersburg33711-1141	NCT05407636	Map
FL	Retina Vitreous Associates of Florida (Site 049)	St. Petersburg33711	NCT07440225	Map
FL	East Florida Eye Institute	Stuart34994	NCT07064759	Map
FL	Southern Vitreoretinal Associates	Tallahassee32308	NCT07449936	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06121180	Map
FL	Retina Associates of Florida, LLC	Tampa33609	NCT07440225	Map
FL	Retina Vitreous Associates of Florida	Tampa33607	NCT05197270	Map
FL	Retina Vitreous Associates of Florida	Tampa33617	NCT07064759	Map
FL	Retina Vitreous Associates of Florida	Tampa33617	NCT07440225	Map
FL	Retina Vitreous Associates of Florida	Tampa33617	NCT07449923	Map
FL	Retina Specialists of Tampa	Wesley Chapel33544	NCT07449936	Map
FL	Center for Retina and Macular Disease /ID# 256335	Winter Haven33880	NCT05407636	Map
GA	Adverum Clinical Site 182	Augusta30909	NCT07482176	Map
GA	CBCC Global Research Site:001	Augusta30909	NCT06132035	Map
GA	Georgia Retina	Marietta30060	NCT07449936	Map
GA	Georgia Retina - Marietta /ID# 256264	Marietta30060	NCT05407636	Map
GA	Thomas Eye Group	Sandy Springs30328	NCT07064759	Map
HI	Retina Consultants of Hawaii	‘Aiea96701	NCT07449936	Map
HI	Retina Consultants of Hawaii /ID# 256278	‘Aiea96701	NCT05407636	Map
IL	Northwestern Memorial Hospital - Department of Ophthalmology /ID# 256379	Chicago60611-2987	NCT05407636	Map
IL	University of Chicago Medical Center	Chicago60637	NCT06121180	Map
IL	Retina Associates	Elmhurst60126	NCT07449923	Map
IL	Retina Associates, Ltd.	Elmhurst60126	NCT07064759	Map
IL	Lemont, IL	Lemont60439	NCT07205887	Map
IL	Lemont, Illinois	Lemont60439	NCT07205887	Map
IL	University Retina & Macula Associates, P.C.	Lemont60439	NCT07496567	Map
IL	University Retina and Macula Associates	Lemont60439	NCT07449923	Map
IL	University Retina and Macula Associates	Oak Forest60452	NCT05197270	Map
IL	University Retina and Macula Associates, PC	Oak Forest60452	NCT07064759	Map
IL	Illinois Retina Associates	Oak Park60304	NCT07064759	Map
IL	Illinois Retina Associates	Oak Park60304	NCT07440225	Map
IL	Illinois Retina Associates, S.C.	Oak Park60304	NCT07449923	Map
IL	Red River Research Partners	Plainfield60586	NCT07449936	Map
IL	Springfield Clinic	Springfield62703	NCT07064759	Map
IL	Springfield Clinic - First /ID# 256371	Springfield62702	NCT05407636	Map
IN	Adverum Clinical Site 195	Carmel46032	NCT07482176	Map
IN	Associated Vitreoretinal & Uveitis Consultants - Carmel	Carmel46032	NCT07449923	Map
IN	CBCC Global Research Site:004	Carmel46290	NCT06132035	Map
IN	Midwest Eye Institute - Carmel	Carmel11220	NCT07449936	Map
IN	Retina Partners Midwest	Carmel46290	NCT05197270	Map
IN	Retina Partners Midwest, PC	Carmel46032	NCT07064759	Map
IN	Retina Partners Midwest, PC /ID# 256277	Indianapolis46290	NCT05407636	Map
KS	Retina Associates - Lenexa /ID# 258296	Lenexa66215	NCT05407636	Map
KY	The Eye Care Institute	Louisville40206	NCT07449923	Map
LA	Haik Humble Eye Center	West Monroe71291	NCT07449936	Map
ME	Maine Eye Center - Marginal Way Campus /ID# 256391	Portland04101	NCT05407636	Map
MD	The Retina Care Center	Baltimore21209	NCT07064759	Map
MD	Retina Group of Washington	Chevy Chase20815	NCT07449936	Map
MD	Adverum Clinical Site 204	Hagerstown21740	NCT07482176	Map
MD	Cumberland Valley Retina Consultants	Hagerstown21740	NCT05197270	Map
MD	Cumberland Valley Retina Consultants	Hagerstown21740	NCT07064759	Map
MD	Cumberland Valley Retina Consultants (Site 007)	Hagerstown21740	NCT07440225	Map
MD	Hagerstown, Maryland	Hagerstown21740	NCT07205887	Map
MD	Hagerstown, MD	Hagerstown21740	NCT07205887	Map
MD	Mid Atlantic Retina Specialist	Hagerstown21740	NCT07064759	Map
MD	Mid Atlantic Retina Specialists	Hagerstown21740	NCT07496567	Map
MD	Mid Atlantic Retina Specialists - Hagerstown	Hagerstown21740	NCT07449923	Map
MD	Retina Specialists - Towson	Towson21204	NCT07449936	Map
MA	Ophthalmic Consultants of Boston /ID# 256233	Boston02114	NCT05407636	Map
MA	Ophthalmic Consultants of Boston & Boston Eye Surgery and Laser Center	Boston02114	NCT05197270	Map
MA	New England Retina Consultants	Springfield01107	NCT07064759	Map
MA	New England Retina Consultants	Springfield01107	NCT07449936	Map
MA	Vitreo Retinal Associates - Worcester /ID# 266008	Worcester01605	NCT05407636	Map
MI	Retina Associates of Michigan	Grand Blanc48439	NCT07449936	Map
MI	Retina Associates of Michigan /ID# 256393	Grand Blanc48439	NCT05407636	Map
MI	Foundation for Vision Research	Grand Rapids49546	NCT07064759	Map
MI	Foundation for Vision Research	Grand Rapids49546	NCT07449936	Map
MI	Foundation for Vision Research (Site 073)	Grand Rapids49546	NCT07440225	Map
MI	Associated Retinal Consultants /ID# 256269	Royal Oak48073	NCT05407636	Map
MN	Retina Consultants of Minnesota	Edina55435	NCT07496567	Map
MN	VitreoRetinal Surgery PLLC DBA Retina Consultants of Minnesota /ID# 256272	Edina55435	NCT05407636	Map
MN	Mayo Clinic - Rochester /ID# 258295	Rochester55905-0001	NCT05407636	Map
MS	Adverum Clinical Site 216	Jackson39202	NCT07482176	Map
MS	Madison, Mississippi	Madison39110	NCT07205887	Map
MS	Madison, MS	Madison39110	NCT07205887	Map
MS	Mississippi Retina Associates (Site 084)	Madison39110	NCT07440225	Map
MS	Mississippi Retina Associates /ID# 270934	Madison39110-2028	NCT05407636	Map
MO	University of Missouri Hospital /ID# 262474	Columbia65212	NCT05407636	Map
MO	The Retina Institute	St Louis63128	NCT07449923	Map
MO	Washington University School of Medicine - St. Louis /ID# 256383	St Louis63108	NCT05407636	Map
NV	Sierra Eye Associates	Reno89502	NCT05197270	Map
NV	Sierra Eye Associates	Reno89502	NCT06942520	Map
NV	Sierra Eye Associates	Reno89502	NCT07064759	Map
NV	Sierra Eye Associates	Reno89502	NCT07449936	Map
NJ	Bloomfield, New Jersey	Bloomfield07003	NCT07205887	Map
NJ	Bloomfield, NJ	Bloomfield07003	NCT07205887	Map
NJ	Envision Ocular, LLC	Bloomfield07003	NCT07064759	Map
NJ	Envision Ocular, LLC	Bloomfield07003	NCT07496567	Map
NJ	Envision Ocular, LLC /ID# 256367	Bloomfield07003	NCT05407636	Map
NJ	Retina Center of New Jersey	Bloomfield07003	NCT07449923	Map
NJ	Monmouth Retina Consultants /ID# 275895	Little Silver07739	NCT05407636	Map
NJ	NJRetina Care Center - Teaneck	Teaneck07666	NCT07449936	Map
NJ	NJ Retina - Toms River	Toms River08755	NCT07449936	Map
NM	Vision Research Center at Eye Associates of New Mexico	Albuquerque87109	NCT07449923	Map
NY	ong Island Vitreoretinal Consultants / Vitreoretinal Consultants of NY (Site 105)	Hauppauge11788	NCT07440225	Map
NY	Adverum Clinical Site 225	Liverpool13088	NCT07482176	Map
NY	Retina Vitreous Surgeons of CNY PC	Liverpool13088	NCT07064759	Map
NY	Retina Vitreous Surgeons of CNY, PC	Liverpool13088	NCT07449923	Map
NY	Retina Vitreous Surgeons of CNY, PC (Site 033)	Liverpool13088	NCT07440225	Map
NY	Northwell Health Center for Advanced Medicine	New Hyde Park11042	NCT06121180	Map
NY	New York Presbyterian Hospital - Columbia University Medical Center	New York10032	NCT07064759	Map
NY	Retina Associates of Western New York	Rochester14620	NCT07449936	Map
NY	Vitreoretinal Consultants of NY	Westbury11590	NCT07064759	Map
NY	VRCNY/Long Island Vitreoretinal Consultants	Westbury11590	NCT07449936	Map
NC	Adverum Clinical Site 196	Asheville28803	NCT07482176	Map
NC	Asheville Eye Associates - Regional Medical Park	Asheville28803	NCT07449936	Map
NC	Asheville Eye Associates- Retina Division /ID# 256355	Asheville28803	NCT05407636	Map
NC	Asheville, North Carolina	Asheville28803	NCT07205887	Map
NC	Cary, North Carolina	Cary27511	NCT07205887	Map
NC	North Carolina Retina Associates	Cary27511	NCT07064759	Map
NC	Duke University Medical Center /ID# 256245	Durham27710	NCT05407636	Map
NC	Adverum Clinical Site 211	Greensboro27401	NCT07482176	Map
NC	Adverum Clinical Site 219	Greensboro27401	NCT07482176	Map
NC	Adverum Clinical Site 220	Hickory28602	NCT07482176	Map
NC	Graystone Eye - Hickory Office	Hickory28602	NCT07449923	Map
NC	Graystone Eye /ID# 256424	Hickory28602	NCT05407636	Map
NC	Adverum Clinical Site 209	Wake Forest27587	NCT07482176	Map
NC	North Carolina Retina Associates	Wake Forest27587	NCT07064759	Map
NC	North Carolina Retina Associates	Wake Forest27587	NCT07449923	Map
NC	Wake Forest, NC	Wake Forest27587	NCT07205887	Map
NC	Wake Forest, North Carolina	Wake Forest27587	NCT07205887	Map
NC	Cape Fear Retinal Associates, PC	Wilmington28401	NCT07449936	Map
NC	Piedmont Retina Specialists, P.A. - Winston-Salem Office	Winston-Salem27103	NCT07449936	Map
ND	CBCC Global Research Site:003	Fargo58104	NCT06132035	Map
OH	Cincinnati Eye Institute	Cincinnati45242	NCT07064759	Map
OH	Cincinnati Eye Institute /ID# 256247	Cincinnati45242-5664	NCT05407636	Map
OH	Ohio State University /ID# 256275	Columbus43210	NCT05407636	Map
OK	Retina Vitreous Center, PLLC	Edmond73013	NCT07449923	Map
OK	Retina Vitreous Center, Research /ID# 256284	Edmond73013	NCT05407636	Map
OK	Tulsa Retina Consultant	Tulsa74114	NCT07449936	Map
OK	Tulsa Retina Consultants	Tulsa74114	NCT07440225	Map
OR	Verum Research, LLC	Eugene97401	NCT05197270	Map
OR	Verum Research, LLC	Eugene947401	NCT07064759	Map
OR	Verum Research, LLC	Eugene97401	NCT07449923	Map
OR	EyeHealth Northwest	Portland97233	NCT07064759	Map
OR	EyeHealth Northwest	Portland97225	NCT07440225	Map
PA	Mid Atlantic Retina	Bethlehem18017	NCT05197270	Map
PA	CBCC Global Research Site:002	Erie16507	NCT06132035	Map
PA	Erie Retina Research	Erie16505	NCT07064759	Map
PA	Erie Retina Research	Erie16507	NCT07449936	Map
PA	Erie Retina Research	Erie16505	NCT07496567	Map
PA	CBCC Global Research Site:007	Philadelphia19141	NCT06132035	Map
PA	Wills Eye Hospital	Philadelphia19107	NCT07449923	Map
SC	Palmetto Retina Center	Aiken29803	NCT07440225	Map
SC	Charleston Neuroscience Institute - Beaufort	Beaufort29902	NCT07449936	Map
SC	Charleston Neuroscience Institute - Beaufort /ID# 256385	Beaufort29902-6216	NCT05407636	Map
SC	Adverum Clinical Site 241	Bluffton29910	NCT07482176	Map
SC	Charleston Neuroscience Institute - Bluffton (Site 124)	Bluffton29910	NCT07440225	Map
SC	Charleston Neuroscience Institute, LLC	Bluffton29910	NCT07064759	Map
SC	Charleston Neuroscience Institute (Site 104)	Charleston29414	NCT07440225	Map
SC	Charleston Neurosciences Institute /ID# 256351	Charleston29414-5896	NCT05407636	Map
SC	Carolinas Centers for Sight, P.C. - Florence Campus	Florence29501	NCT07449923	Map
SC	Retina Consultants of Carolina P.A	Greenville29605	NCT07449936	Map
SC	Adverum Clinical Site 222	Ladson29456	NCT07482176	Map
SC	Charleston Neuroscience Institute	Ladson29456	NCT07496567	Map
SC	Charleston Neurosciences Institute /ID# 256336	Ladson29414-5896	NCT05407636	Map
SC	Carolina Eyecare	Mt. Pleasant29464	NCT07064759	Map
SC	Palmetto Retina Center	West Columbia29169	NCT07064759	Map
SC	Palmetto Retina Center, LLC	West Columbia29169	NCT05197270	Map
SC	West Columbia, SC	West Columbia29169	NCT07205887	Map
SC	West Columbia, South Carolina	West Columbia29169	NCT07205887	Map
SD	Black Hills Regional Eye Institute	Rapid City57701	NCT07064759	Map
SD	Black Hills Regional Eye Institute /ID# 262872	Rapid City57701	NCT05407636	Map
TN	Charles Retina Institute	Germantown38138	NCT07449923	Map
TN	Germantown, Tennessee	Germantown38138	NCT07205887	Map
TN	Southeastern Retina Associates - Johnson City /ID# 256396	Johnson City37604	NCT05407636	Map
TN	Knoxville, Tennessee	Knoxville37922	NCT07205887	Map
TN	Nashville, Tennessee	Nashville37203	NCT07205887	Map
TN	Nashville, TN	Nashville37203	NCT07205887	Map
TN	Tennessee Retina	Nashville37203	NCT05197270	Map
TN	Tennessee Retina	Nashville37203	NCT07449936	Map
TN	Tennessee Retina - Nashville /ID# 256388	Nashville37203-1513	NCT05407636	Map
TN	Tennessee Retina, PC	Nashville37203	NCT07064759	Map
TN	Vanderbilt University Medical Center /ID# 256372	Nashville37232-0011	NCT05407636	Map
TX	Abilene, Texas	Abilene79606	NCT07205887	Map
TX	Retina Research Institute of Texas (Site 010)	Abilene79606	NCT07440225	Map
TX	Retina Research Institute of Texas Integrated Clinical Research	Abilene79606	NCT07449936	Map
TX	Amarillo, Texas	Amarillo79106	NCT07205887	Map
TX	Southwest Retina Specialist - Panhandle Eye group, LLP	Amarillo79106	NCT07064759	Map
TX	Adverum Clinical Site 127	Austin78705	NCT07482176	Map
TX	Austin Clinical Research	Austin78750	NCT05197270	Map
TX	Austin Clinical Research	Austin78750	NCT07064759	Map
TX	Austin Clinical Research LLC	Austin78750	NCT07449923	Map
TX	Austin Research Center for Retina	Austin78705	NCT07440225	Map
TX	Austin Research Center for Retina /ID# 256265	Austin78705	NCT05407636	Map
TX	Austin Retina Associates (Site 012)	Austin78705	NCT07440225	Map
TX	Austin, Texas	Austin78705	NCT07205887	Map
TX	Austin, TX	Austin78705	NCT07205887	Map
TX	Bellaire, Texas	Bellaire77401	NCT07205887	Map
TX	Bellaire, TX	Bellaire77401	NCT07205887	Map
TX	Retina and Vitreous of Texas	Bellaire77401	NCT07449923	Map
TX	Retina Consultants of Texas	Bellaire77401	NCT07449923	Map
TX	Retina Consultants of Texas	Bellaire77401	NCT07496567	Map
TX	Retina Consultants of Texas - Bellaire /ID# 256377	Bellaire77401	NCT05407636	Map
TX	Burleson, Texas	Burleson76028	NCT07205887	Map
TX	Adverum Clinical Site 107	Conroe77384	NCT07482176	Map
TX	Adverum Clinical Site 194	Dallas75231	NCT07482176	Map
TX	Dallas, Texas	Dallas75231	NCT07205887	Map
TX	Dallas, TX	Dallas75231	NCT07205887	Map
TX	Texas Retina Associate	Dallas75231	NCT07064759	Map
TX	Texas Retina Associates	Dallas75231	NCT07449936	Map
TX	Texas Retina Associates /ID# 256259	Dallas75231	NCT05407636	Map
TX	Texas Retina Associates - Fort Worth /ID# 256326	Fort Worth76104	NCT05407636	Map
TX	Mt. Olympus Medical Research	Houston77479	NCT07449936	Map
TX	Retina Consultants of Texas	Katy77494	NCT07449936	Map
TX	Adverum Clinical Site 162	McAllen78503	NCT07482176	Map
TX	Valley Retina Institute, PA	McAllen78503	NCT05197270	Map
TX	Plano, Texas	Plano75075	NCT07205887	Map
TX	Texas Retina (Site 037)	Plano75075	NCT07440225	Map
TX	Texas Retina Associates	Plano75075	NCT07449936	Map
TX	Austin Retina Associates - Round Rock /ID# 256387	Round Rock78681	NCT05407636	Map
TX	Round Rock, Texas	Round Rock78781	NCT07205887	Map
TX	Round Rock, TX	Round Rock78681	NCT07205887	Map
TX	Retina Associates of South Texas	San Antonio78240	NCT05407636	Map
TX	Retina Associates of South Texas	San Antonio78240	NCT07449923	Map
TX	Retina Consultants of Texas /ID# 256382	San Antonio78251	NCT05407636	Map
TX	Retina Consultants of Texas/ID# 259661	San Antonio78240-1655	NCT05407636	Map
TX	San Antonio Eye Center	San Antonio78215	NCT07449923	Map
TX	San Antonio, Texas	San Antonio78240	NCT07205887	Map
TX	San Antonio, TX	San Antonio78240	NCT07205887	Map
TX	Adverum Clinical Site 232	San Marcos78666	NCT07482176	Map
TX	San Marcos, Texas	San Marcos78666	NCT07205887	Map
TX	Adverum Clinical Site 228	Schertz78154	NCT07482176	Map
TX	Retina Consultants of Texas	Schertz78154	NCT07449936	Map
TX	Retina Center Of Texas (Rct) - Southlake /ID# 256281	Southlake76092	NCT05407636	Map
TX	Adverum Clinical Site 231	The Woodlands77384	NCT07482176	Map
TX	Retina Consultants of Texas	The Woodlands77384	NCT07449923	Map
TX	Retina Consultants of Texas (Site 014)	The Woodlands77384	NCT07440225	Map
TX	The Woodlands, Texas	The Woodlands77384	NCT07205887	Map
TX	The Woodlands, TX	The Woodlands77384	NCT07205887	Map
TX	Adverum Clinical Site 237	Tyler75703	NCT07482176	Map
TX	Tyler Retina Consultants	Tyler75703	NCT07064759	Map
TX	Tyler Retina Consultants	Tyler75703	NCT07449923	Map
TX	Strategic Clinical Research	Willow Park76087	NCT07064759	Map
TX	Strategic Clinical Research Group, LLC	Willow Park76087	NCT07449923	Map
TX	Willow Park, Texas	Willow Park76087	NCT07205887	Map
UT	Retina Associates of Utah	Salt Lake City84107	NCT07440225	Map
UT	Retina Associates of Utah	Salt Lake City84107	NCT07449936	Map
UT	Retina Associates of Utah /ID# 256276	Salt Lake City84107	NCT05407636	Map
UT	Rocky Mountain Retina Consultants	Salt Lake City84107	NCT07064759	Map
UT	Salt Lake Retina	West Jordan84088	NCT07449936	Map
UT	West Jordan, Utah	West Jordan84088	NCT07205887	Map
VA	The Retina Group of Washington	Fairfax22031	NCT07449923	Map
VA	Adverum Clinical Site 199	Lynchburg24502	NCT07482176	Map
VA	Piedmont Eye Center	Lynchburg24502	NCT07064759	Map
VA	Piedmont Eye Center	Lynchburg24502	NCT07449936	Map
VA	Piedmont Eye Center (Site 054)	Lynchburg24502	NCT07440225	Map
VA	Vistar Eye Center /ID# 271024	Roanoke24019	NCT05407636	Map
VA	Virginia Retina Center	Warrenton20186	NCT07449936	Map
WA	Pacific Northwest Retina	Bellevue98004	NCT07496567	Map
WA	Pacific Northwest Retina (Site 112)	Burlington98233	NCT07440225	Map
WA	Pacific Northwest Retina	Silverdale98383	NCT07064759	Map
WA	Retina Center NW, PLLC /ID# 256395	Silverdale98383	NCT05407636	Map
WI	Northeast Wisconsin Retina Associates	Appleton54914	NCT07449936	Map
WI	Gundersen Health System - La Crosse Medical Center /ID# 276012	La Crosse54601	NCT05407636	Map
WI	Eye Clinic of Wisconsin	Wausau54403	NCT07064759	Map
WI	Eye Clinic of Wisconsin	Wausau54403	NCT07449923	Map

Aflibercept clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	suspended	not yet recruiting	unknown	no longer available	Total
Early P1				1				1	1		3
P1	1	2		24	3	1			2		33
P1/P2	1	2		9	3		1		3		19
P2	3	7		67	11	7		2	6		103
P2/P3	2			5	1	1			2		11
P3	10	9		60	12	2		2	4		99
P4	3	2		55	3	6		3	21		93
N/A	7	6	1	65	1	4		2	8	1	95

Recruiting Aflibercept clinical trials (38)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07317934	STELLAREfficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)	P3	Neovascular Age-Related Macular Degeneration (nAMD)	332	Jan 2026
NCT07482176	AQUARIUSEfficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)	P3	Neovascular Age-Related Macular Degeneration (nAMD)	284	Mar 2026
NCT05197270	4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration	P1/P2	Neovascular (Wet) Age-Related Macular Degeneration	215	Dec 2021
NCT06121180	Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma	P2	Metastatic Uveal Melanoma	32	Nov 2024
NCT07064759	4FRONT-2Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration	P3	Neovascular Age-Related Macular Degeneration (nAMD)	480	Jul 2025
NCT07389980	PALLASProspective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial	P3	Polypoidal Choroidal Vasculopathy	50	Dec 2026
NCT04663750	TIGERVitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).	P3	Eye Diseases	210	Apr 2021
NCT07449936	DMECOMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME	P3	Diabetic Macular Edema	240	Feb 2026
NCT07449923	DMECAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME	P3	Diabetic Macular Edema	240	Feb 2026
NCT05251636	KILAUEAAdjunct Episcleral Brachytherapy for PCV	P3	Age-Related Macular Degeneration	159	Mar 2025
NCT07496567	TORRONTESA Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)	P2/P3	Macular Degeneration	960	Apr 2026
NCT07440225	MALBECA Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)	P2/P3	Macular Degeneration	960	Mar 2026
NCT07205887	Super TuscanA Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO	P2	Neovascular Age-Related Macular Degeneration (NVAMD)	160	Sep 2025
NCT04519619	NVGStudy to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)	—	Neovascular Glaucoma	480	Nov 2020
NCT07438119	DECADEEfficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients	P4	Diabetic Macular Edema (DME)	114	Mar 2026
NCT07489131	ALVOEYE-HDClinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema	P3	Diabetic Macular Edema	256	Apr 2026
NCT07340372	HOMEHome Monitoring in eAMD Treatment	—	Exudative Age-Related Macular Degeneration	80	May 2026
NCT07365371	PCVA Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)	P4	Polypoidal Choroidal Vasculopathy (PCV)	174	Jan 2026
NCT06942520	ELAAVATEPhase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)	P2	Diabetic Macular Edema	18	Mar 2025
NCT05407636	ASCENTPivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD	P3	AMD	714	Jan 2022
NCT07489586	A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration	P3	Neovascular Age-Related Macular Degeneration (nAMD)	356	Mar 2026
NCT07557121	Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration	P2	Neovascular (Wet) Age-Related Macular Degeneration	35	Jul 2026
NCT06662994	High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy	P4	Diabetic Macular Edema (DME)	15	Jul 2025
NCT06610747	DME HOMEHome- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT	N/A	Diabetic Macular Edema	308	Oct 2024
NCT06315556	UKAn Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)	—	Retinopathy of Prematurity	200	Mar 2024
NCT06929507	Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients	N/A	Renal Function Disorder	60	Mar 2025
NCT06839339	Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD	P2	Wet Age-related Macular Degeneration (wAMD)	40	Feb 2025
NCT07423429	AFLIWESTRetrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration	—	Exudative Age-Related Macular Degeneration	100	Feb 2026
NCT07301775	Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery	P4	Diabetic Retinopathy (DR)	166	Jan 2026
NCT07235527	Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration	—	Age Related Macular Degeneration	54	Nov 2025
NCT05885503	Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema	P3	Diabetic Macular Edema	316	Jun 2023
NCT06683950	Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment	P4	Age-related Macular Degeneration (ARMD)	40	Oct 2024
NCT07434713	ELEV8EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).	—	Age-Related Macular Degeneration (AMD)	50	Jul 2025
NCT07338097	Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema	N/A	Diabetic Macular Edema (DME)	116	Sep 2025
NCT02669953	OPHTH-010915Aflibercept in Recurrent or Persistent CNV	—	Age Related Macular Degeneration	80	Dec 2015
NCT06879301	Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients	Early P1	Diabetic Macular Edema (DME)	60	Oct 2025
NCT06850571	Aflibercept and Bevacizumab for Diabetic Maculopathies	P4	Diabetic Maculopathy	102	Feb 2025
NCT06132035	Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration	P1	Age-related Wet Macular Degeneration	45	Dec 2023

Aflibercept clinical trials by indication

Diabetic Macular Edema (65)

NCT	Acronym	Phase	Status	Title
NCT05930561	—	P2	active not recruiting	4D-150 in Patients With Diabetic Macular Edema
NCT07449936	DME	P3	recruiting	COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923	DME	P3	recruiting	CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07489131	ALVOEYE-HD	P3	recruiting	Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema
NCT06942520	ELAAVATE	P2	recruiting	Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
NCT06610747	DME HOME	N/A	recruiting	Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT
NCT06850922	THAMES	P1/P2	active not recruiting	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
NCT05885503	—	P3	recruiting	Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema
+ 57 more, see All trials below.

Neovascular Age-related Macular Degeneration (26)

NCT	Acronym	Phase	Status	Title
NCT04101877	SAHLVE	P2	active not recruiting	The Sahlgrenska Anti-VEGF Study
NCT05972473	—	P3	active not recruiting	A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
NCT06495918	—	P3	active not recruiting	Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT05342857	—	N/A	unknown	Maximum Treatment Interval With Aflibercept T&E
NCT04757636	COAST	P3	terminated	OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
NCT05941715	FAN	P4	completed	Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration
NCT05891548	ODYSSEY	P2	completed	Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration
NCT05403749	—	P2	completed	A Study of Longer Interval of IVT IBI302 in Subjects With nAMD
+ 18 more, see All trials below.

Macular Degeneration (19)

NCT	Acronym	Phase	Status	Title
NCT07496567	TORRONTES	P2/P3	recruiting	A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
NCT07440225	MALBEC	P2/P3	recruiting	A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT03714308	ANDROMEDA	N/A	completed	Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.
NCT03470103	AQUILA	N/A	completed	A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America
NCT02540954	—	P3	completed	Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
NCT02689518	EAGLE	P4	completed	EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
NCT01756248	AMD	N/A	completed	EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan
NCT02581891	ARIES	P4	completed	Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
+ 11 more, see All trials below.

Neovascular Age-Related Macular Degeneration (17)

NCT	Acronym	Phase	Status	Title
NCT06196840	VENUS	P2	active not recruiting	Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
NCT06223958	—	P3	active not recruiting	Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
NCT06491914	ELARA	P3	active not recruiting	A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
NCT05126966	Diagrid	P3	withdrawn	A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
NCT04423718	PULSAR	P3	completed	Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
NCT04047472	—	P3	completed	Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
NCT04989699	—	P1	completed	Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration
NCT04662944	RAZORBILL	N/A	completed	A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
+ 9 more, see All trials below.

Age Related Macular Degeneration (16)

NCT	Acronym	Phase	Status	Title
NCT07235527	—	N/A	recruiting	Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration
NCT02669953	OPHTH-010915	N/A	recruiting	Aflibercept in Recurrent or Persistent CNV
NCT06878573	—	N/A	completed	Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema
NCT03056079	COVARIANT	P4	unknown	Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept
NCT02550002	—	N/A	completed	Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen
NCT03117634	—	P4	completed	An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
NCT02174211	VITCLEAR	N/A	completed	A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.
NCT02441816	VITAL	P4	completed	VITAL - Individualising Therapy for Neovascular AMD With Aflibercept
+ 8 more, see All trials below.

Wet Macular Degeneration (14)

NCT	Acronym	Phase	Status	Title
NCT04698850	BEY-RAP	P4	withdrawn	Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation
NCT04049266	DAZZLE	P2/P3	terminated	A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
NCT03823287	TENAYA	P3	completed	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
NCT03823300	LUCERNE	P3	completed	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
NCT03022292	IAI-OCTA	P4	completed	The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy
NCT03423823	ZEBRA	P2	completed	Ziv-aflibercept Efficacy in Better Regulating AMD
NCT02289924	PERSEUS-IT	N/A	completed	Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
NCT02279537	RAINBOW	N/A	completed	Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD
+ 6 more, see All trials below.

Wet Age-related Macular Degeneration (13)

NCT	Acronym	Phase	Status	Title
NCT04932980	SPARROW	N/A	active not recruiting	Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
NCT06556368	DAYBREAK	P3	active not recruiting	A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT05727397	—	P3	unknown	Efficacy and Safety of RC28-E Versus Aflibercept
NCT05381948	DAVIO2	P2	completed	Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
NCT03939767	XTEND	N/A	completed	Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
NCT04113538	—	P3	unknown	Treat and Extend Analysis Trial With Aflibercept in Wet-AMD
NCT03290794	IVT-AFL	N/A	completed	Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice
NCT04964089	DAYLIGHT	P3	completed	A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
+ 5 more, see All trials below.

Macular Edema (13)

NCT	Acronym	Phase	Status	Title
NCT04740931	COMINO	P3	completed	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
NCT04740905	BALATON	P3	completed	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
NCT04592419	BEACON	P3	completed	A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
NCT03161912	AURIGA	N/A	completed	A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease
NCT02850263	DRAKO	N/A	completed	A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema
NCT02403128	—	P1	unknown	Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery Macroaneurysms
NCT02818998	VIOLET	P3	completed	Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
NCT02425501	—	N/A	completed	Special Drug Use Investigation of EYLEA for Diabetic Macular Edema
+ 5 more, see All trials below.

Metastatic Colorectal Cancer (13)

NCT	Acronym	Phase	Status	Title
NCT03186326	SAMCO	P2	completed	Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer
NCT04397601	ARBITRATION	N/A	unknown	Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer
NCT03279289	AFEMA	P2	completed	Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen
NCT05178745	—	N/A	completed	Resection Observatory
NCT02331927	PERMAD	P2	unknown	PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer
NCT02173990	PULSAR	P2	terminated	Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).
NCT02624726	MINOAS	P2	unknown	Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment
NCT02970916	POLAF	P2	completed	Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms
+ 5 more, see All trials below.

Age-Related Macular Degeneration (12)

NCT	Acronym	Phase	Status	Title
NCT05251636	KILAUEA	P3	not yet recruiting	Adjunct Episcleral Brachytherapy for PCV
NCT05710471	—	P4	completed	Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E
NCT05587062	—	P3	completed	Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration
NCT06330220	—	P4	completed	Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity
NCT03710564	MERLIN	P3	terminated	Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
NCT02462889	PRO-CON	P2	completed	IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD
NCT02130024	RIVAL	P4	completed	A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
NCT01940887	E10030	P3	terminated	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
+ 4 more, see All trials below.

Diabetic Retinopathy (10)

NCT	Acronym	Phase	Status	Title
NCT06321302	—	P2	active not recruiting	A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
NCT04708145	VOYAGE	P4	completed	Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial
NCT02432547	LADAMO	P4	completed	Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO)
NCT02634333	—	P3	completed	Anti-VEGF Treatment for Prevention of PDR/DME
NCT03531294	—	P2	completed	Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement
NCT02559180	SwapTwo	P4	completed	Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab
NCT01988246	PROMISE	P1/P2	completed	Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery
NCT02924311	APOLLON	N/A	completed	Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
+ 2 more, see All trials below.

Polypoidal Choroidal Vasculopathy (8)

NCT	Acronym	Phase	Status	Title
NCT07389980	PALLAS	P3	recruiting	Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
NCT03941587	—	N/A	completed	Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment
NCT05662943	—	N/A	completed	Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV
NCT04707027	—	N/A	unknown	Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept
NCT02495181	ATLANTIC	P4	completed	Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy
NCT02381730	PCV	N/A	completed	Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment
NCT01871376	EPIC	P4	completed	Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation
NCT02597855	—	N/A	unknown	Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy

Neovascular Age-Related Macular Degeneration (nAMD) (7)

NCT	Acronym	Phase	Status	Title
NCT07317934	STELLAR	P3	recruiting	Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
NCT07482176	AQUARIUS	P3	recruiting	Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
NCT06856577	ARTEMIS	P3	active not recruiting	Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
NCT07064759	4FRONT-2	P3	recruiting	Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06817343	—	P1	active not recruiting	A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
NCT07489586	—	P3	not yet recruiting	A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration
NCT06116890	—	P2	active not recruiting	Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Diabetic Macular Edema (DME) (7)

NCT	Acronym	Phase	Status	Title
NCT07438119	DECADE	P4	not yet recruiting	Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients
NCT06662994	—	P4	recruiting	High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
NCT06116916	—	P2	active not recruiting	Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT07338097	—	N/A	enrolling by invitation	Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema
NCT06879301	—	Early P1	not yet recruiting	Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients
NCT05989126	PFS	P3	completed	Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
NCT02633852	EYLEA	P4	completed	Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema

Colorectal Cancer Metastatic (7)

NCT	Acronym	Phase	Status	Title
NCT01571284	—	P3	completed	Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
NCT01646554	BOS3	P2/P3	withdrawn	Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
NCT02085005	Drop and Go	P2	withdrawn	Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer
NCT01882868	—	P2	completed	A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
NCT01661270	AFLAME	P3	completed	A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy
NCT01670721	AFEQT	P3	completed	Colorectal Cancer Metastatic
NCT01955629	AMOR	P1/P2	terminated	Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient

Retinal Vein Occlusion (6)

NCT	Acronym	Phase	Status	Title
NCT04707625	VEGF	P4	terminated	Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment
NCT02040220	JPMS-CRVO	N/A	completed	Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)
NCT02503540	PERMEATE	P4	completed	Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
NCT02645747	RETRO CRVO	N/A	completed	Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion
NCT01857544	—	P4	unknown	Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy
NCT01012973	GALILEO	P3	completed	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Central Retinal Vein Occlusion (6)

NCT	Acronym	Phase	Status	Title
NCT04793100	PULSOV	N/A	completed	Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections
NCT03810313	RAVEN	P3	terminated	Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
NCT01969708	SCORE2	P3	completed	Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
NCT02800642	CENTERA	P4	completed	Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO
NCT02274259	—	P4	completed	Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
NCT01724554	ANDROID	P1/P2	completed	Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

Choroidal Neovascularization (5)

NCT	Acronym	Phase	Status	Title
NCT02821247	PERSEUS-GR	N/A	completed	Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece
NCT04075188	—	N/A	completed	Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid
NCT03452527	DECO	P2	terminated	Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
NCT02260687	—	N/A	completed	Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization
NCT01578720	IAI	P1	completed	Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome

Proliferative Diabetic Retinopathy (5)

NCT	Acronym	Phase	Status	Title
NCT02858076	AB	P2/P3	completed	Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
NCT02863354	RECOVERY	P2	completed	Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
NCT02976012	LASERLESS	P1/P2	unknown	Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH
NCT02630277	ELYSIAN	P2	unknown	Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN
NCT01813773	ACT	P2/P3	completed	Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study

Neovascular (Wet) Age-Related Macular Degeneration (4)

NCT	Acronym	Phase	Status	Title
NCT05197270	—	P1/P2	recruiting	4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
NCT07557121	—	P2	not yet recruiting	Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration
NCT07390253	—	N/A	active not recruiting	Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration
NCT04126317	CANDELA	P2	completed	Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

Branch Retinal Vein Occlusion (4)

NCT	Acronym	Phase	Status	Title
NCT06146309	—	N/A	completed	Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein Occlusion
NCT03651011	NIRVANA	N/A	completed	Navigated Laser In Branch Retinal Vein Occlusion Study
NCT03802630	RAPTOR	P3	terminated	Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
NCT01521559	VIBRANT	P3	completed	Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

Exudative Age-related Macular Degeneration (4)

NCT	Acronym	Phase	Status	Title
NCT04200248	TOFU	P2	completed	A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration
NCT01961414	RANGE	P4	unknown	Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910
NCT01950741	VAULT	P4	completed	Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
NCT01526070	—	N/A	completed	Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration

Colorectal Neoplasms (4)

NCT	Acronym	Phase	Status	Title
NCT02384759	FOLFA	P2	completed	Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers
NCT00921661	—	P1	completed	Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer
NCT00561470	VELOUR	P3	completed	Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
NCT00851084	AFFIRM	P2	completed	Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer

Neoplasms (4)

NCT	Acronym	Phase	Status	Title
NCT02192541	—	P1	terminated	Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
NCT00545246	—	P1	completed	A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients
NCT00479076	—	P1	completed	A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients
NCT00327171	—	P2	completed	Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer

Exudative Age-Related Macular Degeneration (3)

NCT	Acronym	Phase	Status	Title
NCT07340372	HOME	N/A	not yet recruiting	Home Monitoring in eAMD Treatment
NCT07423429	AFLIWEST	N/A	not yet recruiting	Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration
NCT01796964	—	P2	completed	Efficacy and Safety Study of ESBA1008 Versus EYLEA®

Neovascular Age-related Macular Degeneration (nAMD) (3)

NCT	Acronym	Phase	Status	Title
NCT06398080	SPECTRUM-US	N/A	withdrawn	An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
NCT05769153	NOVA-1	P1/P2	active not recruiting	Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT06929143	—	N/A	active not recruiting	A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema

Retinopathy of Prematurity (3)

NCT	Acronym	Phase	Status	Title
NCT06315556	UK	N/A	recruiting	An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
NCT05705258	—	N/A	active not recruiting	A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)
NCT04101721	BUTTERFLEYE	P3	completed	Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

Eye Diseases (3)

NCT	Acronym	Phase	Status	Title
NCT04663750	TIGER	P3	recruiting	Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
NCT03766425	—	Early P1	completed	Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy.
NCT02811692	CODEX	N/A	completed	Study for Collection of Aflibercept Data in Routine Practice

Age-related Macular Degeneration (3)

NCT	Acronym	Phase	Status	Title
NCT04005352	TALON	P3	completed	Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
NCT01824225	—	P4	completed	Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration
NCT02118831	—	P1/P2	completed	Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF

Central Serous Chorioretinopathy (3)

NCT	Acronym	Phase	Status	Title
NCT02681783	PRaCTICAL	P4	unknown	PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept
NCT01971190	—	P2	completed	Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy
NCT01710332	CONTAIN	P2	completed	The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy

Colorectal Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT03530267	ELDERLY	P2	completed	Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer
NCT01889680	—	P2	withdrawn	Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer
NCT03264274	AUSCOR	P2	withdrawn	Trial of Aflibercept Monotherapy With DCE-US in Chemorefractory Metastatic Colorectal Cancer

Rectal Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT03043729	—	P2	completed	mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer
NCT02340949	RIA	P2	completed	Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer
NCT01749956	RT	P2	completed	5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer

Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT00876044	QUTIE	P1	completed	A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients
NCT00082823	—	P1	completed	Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
NCT00083213	—	P1	completed	Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Diabetic Retinopathy (DR) (2)

NCT	Acronym	Phase	Status	Title
NCT04567550	ALTITUDE®	P2	active not recruiting	RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
NCT07301775	—	P4	not yet recruiting	Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery

Retinal Vasculitis (2)

NCT	Acronym	Phase	Status	Title
NCT07105228	—	N/A	completed	Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
NCT06769412	RV	N/A	completed	A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

Wet Age Related Macular Degeneration (2)

NCT	Acronym	Phase	Status	Title
NCT06683742	wAMD	P3	active not recruiting	A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06668064	wAMD	P3	active not recruiting	A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

Chorioretinal Vascular Disease (2)

NCT	Acronym	Phase	Status	Title
NCT05704725	CVD	P3	completed	A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)
NCT03767738	—	P4	completed	Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe

AMD (2)

NCT	Acronym	Phase	Status	Title
NCT05407636	ASCENT	P3	recruiting	Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT03324542	OIVAEGFFAMDIT	N/A	completed	Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan

Diabetes Mellitus (2)

NCT	Acronym	Phase	Status	Title
NCT04527107	KALAHARI	P2	completed	A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema
NCT05063734	INTEGRAL	P2	terminated	A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

Retinal Disease (2)

NCT	Acronym	Phase	Status	Title
NCT04137120	MAIA	N/A	completed	Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
NCT03712670	—	N/A	completed	Nutraceutical Support With Omega-3

Neovascular Glaucoma (2)

NCT	Acronym	Phase	Status	Title
NCT04519619	NVG	N/A	recruiting	Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
NCT01711879	—	N/A	completed	Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma

Retinopathy of Prematurity (ROP) (2)

NCT	Acronym	Phase	Status	Title
NCT04015180	FIREFLEYE next	P3	completed	Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090
NCT04004208	FIREFLEYE	P3	completed	Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy

Glaucoma, Neovascular (2)

NCT	Acronym	Phase	Status	Title
NCT03639675	VENERA	P3	completed	Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied
NCT02396316	VEGA	P3	completed	Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients

Radiation Retinopathy (2)

NCT	Acronym	Phase	Status	Title
NCT03085784	ARRT	P2	unknown	Intravitreal Aflibercept Injection for Radiation Retinopathy Trial
NCT01579760	—	P1	completed	Intravitreal Aflibercept Injection for Radiation Retinopathy

Corneal Neovascularization (2)

NCT	Acronym	Phase	Status	Title
NCT02797704	—	P1/P2	terminated	Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
NCT01868360	—	P1	terminated	Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea

Visual Impairment Due to Diabetic Macular Edema (2)

NCT	Acronym	Phase	Status	Title
NCT02878681	TIDE DME	P4	withdrawn	24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.
NCT02258009	TIDE DME	P4	withdrawn	Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Mucinous Adenocarcinoma of the Colon (2)

NCT	Acronym	Phase	Status	Title
NCT01652196	—	P2	completed	Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
NCT02235324	—	P2	withdrawn	Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer

Macular Disease (2)

NCT	Acronym	Phase	Status	Title
NCT02321267	—	P4	unknown	Cohort Study of the Clinical Course of Macular Diseases in Kagawa
NCT02081339	—	N/A	unknown	Cohort Study of the Clinical Course of Macular Diseases in Japanese

Neovascular Macular Degeneration (2)

NCT	Acronym	Phase	Status	Title
NCT02120950	PLANET	P4	completed	Aflibercept in Polypoidal Choroidal Vasculopathy
NCT02204683	DRAW	P1	completed	Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration

Recurrent Colon Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT01941173	—	N/A	withdrawn	Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy
NCT00407654	—	P2	completed	VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer

Neoplasm Malignant (2)

NCT	Acronym	Phase	Status	Title
NCT01930552	—	P1	completed	A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies
NCT01148615	—	P1	completed	A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

Adult Anaplastic Astrocytoma (2)

NCT	Acronym	Phase	Status	Title
NCT00650923	—	P1	completed	Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
NCT00369590	—	P2	completed	VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide

Fallopian Tube Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT00390234	—	P2	completed	Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
NCT00436501	—	P1/P2	completed	VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Neoplasms (2)

NCT	Acronym	Phase	Status	Title
NCT00327444	—	P2/P3	completed	Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
NCT00396591	—	P2	completed	AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites

Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT00045266	—	P1	completed	VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
NCT00036946	—	P1	completed	VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Polypoidal Choroidal Vasculopathy (PCV) (1)

NCT	Acronym	Phase	Status	Title
NCT07365371	PCV	P4	not yet recruiting	A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)

Proliferative Diabetic Retinopathy (PDR) (1)

NCT	Acronym	Phase	Status	Title
NCT07118670	HERO	P4	active not recruiting	High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

Neovascular Age-Related Macular Degeneration (NVAMD) (1)

NCT	Acronym	Phase	Status	Title
NCT07205887	Super Tuscan	P2	recruiting	A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

Age-Related Macular Degeneration (AMD) (1)

NCT	Acronym	Phase	Status	Title
NCT07434713	ELEV8	N/A	recruiting	EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).

Renal Function Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT06929507	—	N/A	recruiting	Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients

Macular Neovascularization Secondary to Age-Related Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT06864988	—	P3	active not recruiting	4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Diabetic Maculopathy (1)

NCT	Acronym	Phase	Status	Title
NCT06850571	—	P4	recruiting	Aflibercept and Bevacizumab for Diabetic Maculopathies

Wet Age-related Macular Degeneration (wAMD) (1)

NCT	Acronym	Phase	Status	Title
NCT06839339	—	P2	not yet recruiting	Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD

Diabetic Retinopathy, DR (1)

NCT	Acronym	Phase	Status	Title
NCT07526857	GLIA-MAC	N/A	completed	Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy

Metastatic Uveal Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT06121180	—	P2	recruiting	Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Age-related Macular Degeneration (ARMD) (1)

NCT	Acronym	Phase	Status	Title
NCT06683950	—	P4	recruiting	Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment

Visual Impairment (1)

NCT	Acronym	Phase	Status	Title
NCT06075147	—	N/A	active not recruiting	The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Anti-VEGF Therapy (1)

NCT	Acronym	Phase	Status	Title
NCT07096713	Anti-VEGF	N/A	completed	Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema

Age-related Wet Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT06132035	—	P1	recruiting	Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Macular Edema Secondary to Retinal Vein Occlusion (1)

NCT	Acronym	Phase	Status	Title
NCT05850520	QUASAR	P3	completed	A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

Neovascular (Wet) Age-related Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT05473715	XPAND	P4	terminated	A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment

Pachychoroid Neovasculopathy (1)

NCT	Acronym	Phase	Status	Title
NCT05662410	—	P4	completed	Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy

Neovascular (Wet) AMD (1)

NCT	Acronym	Phase	Status	Title
NCT05155293	ALVOEYE	P3	completed	Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)

Neovascular Age-related Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT05222633	—	N/A	unknown	Anti-VEGF in Real-world

Myopic Choroidal Neovascularization (1)

NCT	Acronym	Phase	Status	Title
NCT04524910	REALM	N/A	completed	A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)

Diabetic Macula Edema (1)

NCT	Acronym	Phase	Status	Title
NCT04079231	BUZZARD	P3	withdrawn	Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Retinopathy, Diabetic (1)

NCT	Acronym	Phase	Status	Title
NCT04702048	PRAVA	P4	withdrawn	Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye

Non-Ischemic Central Retinal Vein Occlusion With Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT05282420	—	P4	unknown	Ranibizumab Versus Aflibercept for CRVO in Young Patients.

Retinal Angiomatous Proliferation (1)

NCT	Acronym	Phase	Status	Title
NCT04655482	—	P4	unknown	Treat-and-extend Using Aflibercept for Type 3 Neovascularization

Thyroid Eye Disease (1)

NCT	Acronym	Phase	Status	Title
NCT04311606	AcTED	P2	completed	Anti-VEGF Therapy for Acute Thyroid Eye Disease

Retinal Detachment With Multiple Breaks, Unspecified Eye (1)

NCT	Acronym	Phase	Status	Title
NCT04580147	PREVENT-PVR	P2	unknown	Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair

Cancer Colorectal (1)

NCT	Acronym	Phase	Status	Title
NCT04392479	TWICE-IRI	P3	unknown	TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.

Neovascular (Wet) Age-related Macular Degeneration (AMD) (1)

NCT	Acronym	Phase	Status	Title
NCT04270747	—	P3	completed	A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

Recurrent or Metastatic Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04810585	—	P4	unknown	Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer

Uveal Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT03712904	—	P2	terminated	Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

Macular Telangiectasia (1)

NCT	Acronym	Phase	Status	Title
NCT03845049	TELeMAC	P3	terminated	Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1

Clinically Significant Macular Edema Due to Diabetes Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT03999125	—	P4	unknown	Anti-VEGF Therapy Versus Dexamethasone Implant for DME

Central Retinal Vein Occlusion With Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT04290195	—	P1/P2	completed	Use of Ziv Aflibercept in Different Retinal Diseases

Irvine-Gass Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT03396861	ACME	P1	terminated	Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept

Intraocular Pressure (1)

NCT	Acronym	Phase	Status	Title
NCT04970251	—	N/A	completed	Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma

Branch Retinal Vein Occlusion with Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT03709745	—	P4	completed	Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

Diabetic Vitreous Hemorrhage (1)

NCT	Acronym	Phase	Status	Title
NCT04153253	—	P4	completed	Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage

Branch Retinal Vein Occlusion With Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT03405376	—	P4	unknown	Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion

Metastatic Colon Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03730558	ZETA	N/A	completed	ZETA : Prospective Observational Study

Ocular Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT03172299	PROTECT	P3	completed	Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma

Symtomatic Macular Polypoidal Choroidal Vasculopathy (1)

NCT	Acronym	Phase	Status	Title
NCT02860858	PCV	P4	completed	Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)

Inflammatory Choroidal Neovascularization (1)

NCT	Acronym	Phase	Status	Title
NCT02556229	ALINEA	P2	completed	Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory CNV in Young Patients (ALINEA).

Macular Edema, Diabetic (1)

NCT	Acronym	Phase	Status	Title
NCT02788877	VIBIM	P4	unknown	Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)

Macular Oedema (1)

NCT	Acronym	Phase	Status	Title
NCT02661711	AMOUR	P2	completed	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study

Nonproliferative Diabetic Retinopathy (1)

NCT	Acronym	Phase	Status	Title
NCT02718326	PANORAMA	P3	completed	Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

Choroidal Neovascularization in Angioid Streaks (1)

NCT	Acronym	Phase	Status	Title
NCT02573038	ASTRID	P2	withdrawn	Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID).

Age-related Macular Degeneration (AMD) (1)

NCT	Acronym	Phase	Status	Title
NCT02585401	—	N/A	completed	Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

Adverse Effect of Radiation Therapy (1)

NCT	Acronym	Phase	Status	Title
NCT02586727	—	P2	completed	Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy

Pseudoxanthoma Elasticum (1)

NCT	Acronym	Phase	Status	Title
NCT02537054	EyNeP	P2	completed	Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)

Center-involved Diabetic Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT04288232	—	P3	completed	Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan

Retinal Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT02646670	—	P4	completed	Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema

Idiopathic Choroidal Neovascularization (1)

NCT	Acronym	Phase	Status	Title
NCT02257502	INTUITION	P2	completed	Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients

Naive Patients With Uncomplicated Proliferative Diabetic Retinopathy (1)

NCT	Acronym	Phase	Status	Title
NCT02151695	—	P2	completed	Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.

Pigment Epithelial Detachment (1)

NCT	Acronym	Phase	Status	Title
NCT03370380	PED	N/A	completed	Aflibercept in Patients With Pigment Epithelial Detachments (PED)

Cystoid Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT02392364	EVADE	P4	completed	Variable Interval Versus Set Interval Aflibercept for DME

Wet Age-Related Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT02257632	TIDE AMD	P4	completed	Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Clinical Stage IV Cutaneous Melanoma AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT02298959	—	P1	active not recruiting	Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Neovascularization (1)

NCT	Acronym	Phase	Status	Title
NCT02486484	Zaltrap	P2	unknown	Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection

Clinically Significant Diabetic Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT02734407	Endurance3	P4	completed	Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema

Type 3 Choroidal Neovascularization (1)

NCT	Acronym	Phase	Status	Title
NCT02320474	ATTRACT	P4	completed	Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

Advanced Malignant Solid Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT02159989	—	P1	completed	Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Multiple Endocrine Neoplasia Type 1 (1)

NCT	Acronym	Phase	Status	Title
NCT02101918	—	P2	completed	Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

Neovascular Polypoidal Choroidal Vasculopathy (1)

NCT	Acronym	Phase	Status	Title
NCT02092532	RIVAL	P4	unknown	Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)

Glaucoma (1)

NCT	Acronym	Phase	Status	Title
NCT02641457	—	P3	completed	Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis

Polypoidal Choroidal Vasculopathy Without Active Polyp (1)

NCT	Acronym	Phase	Status	Title
NCT02072408	—	P4	completed	Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy

Choroidal Retinal Neovascularization (1)

NCT	Acronym	Phase	Status	Title
NCT02033018	AflibxMyopia	P4	unknown	Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization

Pattern Dystrophy of Macula (1)

NCT	Acronym	Phase	Status	Title
NCT01965041	AVA	N/A	withdrawn	Intravitreal Aflibercept Injections In The Treatment Of Pattern Dystrophy

Metastatic Colorectal Cancers (1)

NCT	Acronym	Phase	Status	Title
NCT01843725	MOMENTUM1	P1	completed	Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers

Macular Edema With Central Retinal Vein Occlusions (1)

NCT	Acronym	Phase	Status	Title
NCT01870427	NEWTON	P4	completed	NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions

Unresectable Metastatic Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01802684	VELVET	P2	completed	OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer

Vitreous Hemorrhage (1)

NCT	Acronym	Phase	Status	Title
NCT01805297	—	P2	completed	Aflibercept Injection for Proliferative Diabetic Retinopathy

Ocular Histoplasmosis (1)

NCT	Acronym	Phase	Status	Title
NCT01790893	HANDLE	P1/P2	unknown	Treatment for Presumed Ocular Histoplasmosis

Carcinoid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT01782443	—	P2	completed	Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

Esophageal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01747551	—	P2	completed	FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

Submacular Vascularized Pigment Epithelial Detachments (1)

NCT	Acronym	Phase	Status	Title
NCT01722656	EVEN	P4	completed	Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment

Age - Related Macular Degeneration (AMD) (1)

NCT	Acronym	Phase	Status	Title
NCT01722045	RE-VIEW	P4	completed	Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT01688960	—	P1	completed	Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies

Exudative Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT01617148	—	P4	completed	Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept

Fibrovascular Pigment Epithelial Detachment (1)

NCT	Acronym	Phase	Status	Title
NCT01495208	FVPED	P4	withdrawn	Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment

Metastatic Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT01258855	—	P2	completed	Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Extensive Stage Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00828139	—	P2	completed	S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Advanced Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00794417	—	P1/P2	terminated	A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma

Recurrent Thyroid Gland Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00729157	—	P2	completed	Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Unspecified Childhood Solid Tumor, Protocol Specific (1)

NCT	Acronym	Phase	Status	Title
NCT00622414	—	P1	completed	Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors

Lymphoma, Non-Hodgkin (1)

NCT	Acronym	Phase	Status	Title
NCT00644124	R-CHOP	P1	completed	Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma

Pancreatic Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT00574275	VANILLA	P3	terminated	Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

Recurrent Endometrial Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00462826	—	P2	completed	VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer

Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative (1)

NCT	Acronym	Phase	Status	Title
NCT00509249	—	P2	terminated	Aflibercept in Treating Patients With Myelodysplastic Syndromes

Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00532155	VITAL	P3	completed	A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Prostatic Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT00519285	VENICE	P3	completed	Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

Ciliary Body and Choroid Melanoma, Medium/Large Size (1)

NCT	Acronym	Phase	Status	Title
NCT00450255	—	P2	completed	VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Stage II Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT00437034	—	P2	terminated	Aflibercept for Relapsed Multiple Myeloma

Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00369655	—	P2	completed	VEGF Trap in Treating Patients With Metastatic Breast Cancer

Adenocarcinoma of the Bladder (1)

NCT	Acronym	Phase	Status	Title
NCT00407485	—	P2	completed	VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

Pulmonary Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT00284141	—	P2	completed	Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

Retinal Hemangioma (1)

NCT	Acronym	Phase	Status	Title
NCT01714115	—	N/A	no longer available	Use of Eylea for the Treatment of an Optic Nerve Hemangioma

Aflibercept pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
HERO	NCT07118670	P4	active not recruiting	Proliferative Diabetic Retinopathy (PDR)	40	—
DECADE	NCT07438119	P4	not yet recruiting	Diabetic Macular Edema (DME)	114	—
PCV	NCT07365371	P4	not yet recruiting	Polypoidal Choroidal Vasculopathy (PCV)	174	—
DEUTERON	NCT06591598	P4	completed	Diabetic Macular Edema	51	—
FAN	NCT05941715	P4	completed	Neovascular Age-related Macular Degeneration	70	—
NEW DAY	NCT04469595	P4	active not recruiting	Diabetic Macular Edema	300	PMID 41887289
VOYAGE	NCT04708145	P4	completed	Diabetic Retinopathy	41	PMID 41295257
VISION-AF	NCT05511038	P4	completed	Diabetic Macular Edema	100	—
STAMP	NCT03832179	P4	completed	Diabetic Macular Edema	16	PMID 27493795
COVARIANT	NCT03056079	P4	unknown	Age Related Macular Degeneration	168	—
PRAVA	NCT04702048	P4	withdrawn	Retinopathy, Diabetic	0	—
FORESIGHT	NCT03780361	P4	completed	Diabetic Macular Edema	23	PMID 29392317
PRECISION	NCT04411693	P4	completed	Diabetic Macular Edema	23	—
VEGF	NCT04707625	P4	terminated	Retinal Vein Occlusion	17	PMID 25068637
XPAND	NCT05473715	P4	terminated	Neovascular (Wet) Age-related Macular Degeneration	3	—
BEY-RAP	NCT04698850	P4	withdrawn	Wet Macular Degeneration	0	—
PRaCTICAL	NCT02681783	P4	unknown	Central Serous Chorioretinopathy	90	—
LADAMO	NCT02432547	P4	completed	Diabetic Retinopathy	48	—
DEAR	NCT03197480	P4	unknown	Diabetic Macular Edema	36	—
SwapTwo	NCT02559180	P4	completed	Diabetic Retinopathy	20	PMID 31367468
IAI-OCTA	NCT03022292	P4	completed	Wet Macular Degeneration	26	PMID 25887628
VIBIM	NCT02788877	P4	unknown	Macular Edema, Diabetic	48	PMID 21459215
ATLANTIC	NCT02495181	P4	completed	Polypoidal Choroidal Vasculopathy	50	PMID 34348351
EAGLE	NCT02689518	P4	completed	Macular Degeneration	50	—
TRISTAR	NCT03468296	P4	unknown	Neovascular Age-related Macular Degeneration	22	PMID 36728874
CENTERA	NCT02800642	P4	completed	Central Retinal Vein Occlusion	162	PMID 33556381
DME	NCT04087746	P4	completed	Diabetic Macular Edema	400	—
ARIES	NCT02581891	P4	completed	Macular Degeneration	287	PMID 35821380
PCV	NCT02860858	P4	completed	Symtomatic Macular Polypoidal Choroidal Vasculopathy	50	—
MPL	NCT03866746	P4	completed	Diabetic Macular Edema	51	—
ATTRACT	NCT02320474	P4	completed	Type 3 Choroidal Neovascularization	26	—
EVADE	NCT02392364	P4	completed	Cystoid Macular Edema	50	—
EYLEA	NCT02633852	P4	completed	Diabetic Macular Edema (DME)	48	—
Endurance	NCT02297204	P4	completed	Diabetic Macular Edema	9	—
PERMEATE	NCT02503540	P4	completed	Retinal Vein Occlusion	31	PMID 31757691
VITAL	NCT02441816	P4	completed	Age Related Macular Degeneration	50	PMID 32557168
ALTAIR	NCT02305238	P4	completed	Wet Macular Degeneration	288	PMID 35503499
Eylea	NCT02924987	P4	unknown	Diabetic Macular Edema	40	—
RIVAL	NCT02130024	P4	completed	Age-Related Macular Degeneration	281	PMID 32374423
TIDE DME	NCT02878681	P4	withdrawn	Visual Impairment Due to Diabetic Macular Edema	0	—
Endurance3	NCT02734407	P4	completed	Clinically Significant Diabetic Macular Edema	9	—
AQUA	NCT02581995	P4	completed	Macular Edema	560	—
PLANET	NCT02120950	P4	completed	Neovascular Macular Degeneration	333	PMID 41903075
TIDE AMD	NCT02257632	P4	completed	Wet Age-Related Macular Degeneration	41	—
SALT	NCT01958918	P4	completed	Neovascular Age-related Macular Degeneration	712	—
SHIFT-2	NCT02002377	P4	terminated	Age Related Macular Degeneration	23	—
TIDE DME	NCT02258009	P4	withdrawn	Visual Impairment Due to Diabetic Macular Edema	0	—
EPIC	NCT01871376	P4	completed	Polypoidal Choroidal Vasculopathy	25	PMID 27465105
NEWTON	NCT01870427	P4	completed	Macular Edema With Central Retinal Vein Occlusions	20	PMID 31016030
RANGE	NCT01961414	P4	unknown	Exudative Age-related Macular Degeneration	45	—
EYLEA	NCT01918878	P4	unknown	Neovascular Age-related Macular Degeneration	48	—
RIVAL	NCT02092532	P4	unknown	Neovascular Polypoidal Choroidal Vasculopathy	20	—
ROLL	NCT01670162	P4	unknown	Age Related Macular Degeneration	30	—
EVEN	NCT01722656	P4	completed	Submacular Vascularized Pigment Epithelial Detachments	40	—
RE-VIEW	NCT01722045	P4	completed	Age - Related Macular Degeneration (AMD)	154	—
VAULT	NCT01950741	P4	completed	Exudative Age-related Macular Degeneration	48	PMID 20719300
MACBETH	NCT01896284	P4	completed	Wet Macular Degeneration	46	—
AflibxMyopia	NCT02033018	P4	unknown	Choroidal Retinal Neovascularization	20	—
TURF	NCT01543568	P4	completed	Age Related Macular Degeneration	46	PMID 24518078
FVPED	NCT01495208	P4	withdrawn	Fibrovascular Pigment Epithelial Detachment	0	—
STELLAR	NCT07317934	P3	recruiting	Neovascular Age-Related Macular Degeneration (nAMD)	332	—
AQUARIUS	NCT07482176	P3	recruiting	Neovascular Age-Related Macular Degeneration (nAMD)	284	—
ARTEMIS	NCT06856577	P3	active not recruiting	Neovascular Age-Related Macular Degeneration (nAMD)	311	—
4FRONT-2	NCT07064759	P3	recruiting	Neovascular Age-Related Macular Degeneration (nAMD)	480	—
PALLAS	NCT07389980	P3	recruiting	Polypoidal Choroidal Vasculopathy	50	—
TIGER	NCT04663750	P3	recruiting	Eye Diseases	210	PMID 40229856
DME	NCT07449936	P3	recruiting	Diabetic Macular Edema	240	—
DME	NCT07449923	P3	recruiting	Diabetic Macular Edema	240	—
KILAUEA	NCT05251636	P3	not yet recruiting	Age-Related Macular Degeneration	159	—
ALVOEYE-HD	NCT07489131	P3	recruiting	Diabetic Macular Edema	256	—
ASCENT	NCT05407636	P3	recruiting	AMD	714	—
wAMD	NCT06683742	P3	active not recruiting	Wet Age Related Macular Degeneration	400	—
wAMD	NCT06668064	P3	active not recruiting	Wet Age Related Macular Degeneration	400	—
DAYBREAK	NCT06556368	P3	active not recruiting	Wet Age-related Macular Degeneration	675	—
ELARA	NCT06491914	P3	active not recruiting	Neovascular Age-Related Macular Degeneration	1,118	—
PHOTONiC	NCT06422507	P3	completed	Diabetic Macular Edema	333	—
Diagrid	NCT05126966	P3	withdrawn	Neovascular Age-Related Macular Degeneration	0	—
FIREFLEYE next	NCT04015180	P3	completed	Retinopathy of Prematurity (ROP)	100	PMID 38687481
QUASAR	NCT05850520	P3	completed	Macular Edema Secondary to Retinal Vein Occlusion	892	—
COAST	NCT04757636	P3	terminated	Neovascular Age-related Macular Degeneration	998	—
TELeMAC	NCT03845049	P3	terminated	Macular Telangiectasia	16	—
PROTECT	NCT03172299	P3	completed	Ocular Melanoma	57	—
ALVOEYE	NCT05155293	P3	completed	Neovascular (Wet) AMD	413	PMID 40512025
PULSAR	NCT04423718	P3	completed	Neovascular Age-Related Macular Degeneration	1,011	PMID 41411005
TWICE-IRI	NCT04392479	P3	unknown	Cancer Colorectal	202	PMID 14657227
PFS	NCT05989126	P3	completed	Diabetic Macular Edema (DME)	35	—
GLEAM	NCT04611152	P3	terminated	Diabetic Macular Edema	460	—
GLIMMER	NCT04603937	P3	terminated	Diabetic Macular Edema	459	—
COMINO	NCT04740931	P3	completed	Macular Edema	729	PMID 38280653
BALATON	NCT04740905	P3	completed	Macular Edema	553	PMID 36912792
RHINE	NCT03622593	P3	completed	Diabetic Macular Edema	951	PMID 38852921
MAGELLAN-AMD	NCT04522167	P3	completed	Neovascular Age-related Macular Degeneration	434	PMID 41494750
DAYLIGHT	NCT04964089	P3	completed	Wet Age-related Macular Degeneration	557	—
CVD	NCT05704725	P3	completed	Chorioretinal Vascular Disease	49	—
BUZZARD	NCT04079231	P3	withdrawn	Diabetic Macula Edema	0	—
KINGLET	NCT04058067	P3	completed	Diabetic Macular Edema	266	—
BEACON	NCT04592419	P3	completed	Macular Edema	568	—
TALON	NCT04005352	P3	completed	Age-related Macular Degeneration	734	—
AMD	NCT04480463	P3	completed	Wet Age-related Macular Degeneration	576	—
BUTTERFLEYE	NCT04101721	P3	completed	Retinopathy of Prematurity	127	—
AMD	NCT04450329	P3	completed	Neovascular Age-related Macular Degeneration	449	PMID 37289448
TENAYA	NCT03823287	P3	completed	Wet Macular Degeneration	671	PMID 37294433
LUCERNE	NCT03823300	P3	completed	Wet Macular Degeneration	658	PMID 38382813
DRCR AC	NCT03321513	P3	completed	Diabetic Macular Edema	270	PMID 35833805
KESTREL	NCT03481634	P3	completed	Diabetic Macular Edema	566	—
RO6867461	NCT03622580	P3	completed	Diabetic Macular Edema	940	PMID 38158159
RAVEN	NCT03810313	P3	terminated	Central Retinal Vein Occlusion	493	—
RAPTOR	NCT03802630	P3	terminated	Branch Retinal Vein Occlusion	450	—
MERLIN	NCT03710564	P3	terminated	Age-Related Macular Degeneration	535	—
KITE	NCT03481660	P3	completed	Diabetic Macular Edema	360	—
PANDA-2	NCT03630952	P3	terminated	Neovascular Age-related Macular Degeneration	1,157	—
PANDA-1	NCT03577899	P3	terminated	Neovascular Age-related Macular Degeneration	1,157	—
SCORE2	NCT01969708	P3	completed	Central Retinal Vein Occlusion	362	PMID 28492910
KINGFISHER	NCT03917472	P3	completed	Diabetic Macular Edema	517	PMID 37971723
FIREFLEYE	NCT04004208	P3	completed	Retinopathy of Prematurity (ROP)	113	PMID 35881122
VIOLET	NCT02818998	P3	completed	Macular Edema	463	PMID 35412227
PANORAMA	NCT02718326	P3	completed	Nonproliferative Diabetic Retinopathy	402	PMID 34351414
Protocol T	NCT01627249	P3	completed	Diabetic Macular Edema	660	PMID 25692915
VENERA	NCT03639675	P3	completed	Glaucoma, Neovascular	16	PMID 33330959
SAPPHIRE	NCT02980874	P3	terminated	Macular Edema	460	—
Protocol V	NCT01909791	P3	completed	Diabetic Macular Edema	702	PMID 31037289
HAWK	NCT02307682	P3	completed	Neovascular Age-Related Macular Degeneration	1,775	PMID 38360182
HARRIER	NCT02434328	P3	completed	Neovascular Age-Related Macular Degeneration	1,048	PMID 39033924
E10030	NCT01940887	P3	terminated	Age-Related Macular Degeneration	645	PMID 30957581
VEGA	NCT02396316	P3	completed	Glaucoma, Neovascular	54	PMID 37010901
ARI2	NCT02157077	P3	completed	Macular Degeneration	90	PMID 30681643
AFLAME	NCT01661270	P3	completed	Colorectal Cancer Metastatic	332	PMID 30117334
AFEQT	NCT01670721	P3	completed	Colorectal Cancer Metastatic	175	—
VIVID EAST	NCT01783886	P3	completed	Macular Edema	381	PMID 31904267
VISTA DME	NCT01363440	P3	completed	Diabetic Macular Edema	466	PMID 27847634
VIBRANT	NCT01521559	P3	completed	Branch Retinal Vein Occlusion	183	PMID 32633861
AMD	NCT00964795	P3	completed	Neovascular Age-related Macular Degeneration	323	—
VELOUR	NCT00561470	P3	completed	Colorectal Neoplasms	1,226	PMID 22949147
VENICE	NCT00519285	P3	completed	Prostatic Neoplasms	1,224	PMID 23742877
GALILEO	NCT01012973	P3	completed	Retinal Vein Occlusion	177	PMID 24084497
VITAL	NCT00532155	P3	completed	Carcinoma	913	PMID 22965962
VIEW 2	NCT00637377	P3	completed	Macular Degeneration	1,240	PMID 24084500
VIEW1	NCT00509795	P3	completed	Macular Degeneration	1,217	—
VANILLA	NCT00574275	P3	terminated	Pancreatic Neoplasm	546	PMID 23642329
VENUS	NCT06196840	P2	active not recruiting	Neovascular Age-Related Macular Degeneration	50	—
Super Tuscan	NCT07205887	P2	recruiting	Neovascular Age-Related Macular Degeneration (NVAMD)	160	—
ELAAVATE	NCT06942520	P2	recruiting	Diabetic Macular Edema	18	—
SAHLVE	NCT04101877	P2	active not recruiting	Neovascular Age-related Macular Degeneration	402	—
ALTITUDE®	NCT04567550	P2	active not recruiting	Diabetic Retinopathy (DR)	139	—
UBX1325	NCT06011798	P2	completed	Diabetic Macular Edema	52	—
SAMCO	NCT03186326	P2	completed	Metastatic Colorectal Cancer	132	PMID 40531517
AcTED	NCT04311606	P2	completed	Thyroid Eye Disease	11	PMID 27423310
VERONA	NCT06099184	P2	completed	Diabetic Macular Edema	27	—
ODYSSEY	NCT05891548	P2	completed	Neovascular Age-related Macular Degeneration	60	—
DAVIO2	NCT05381948	P2	completed	Wet Age-related Macular Degeneration	161	—
ELDERLY	NCT03530267	P2	completed	Colorectal Cancer	124	PMID 21570111
PREVENT-PVR	NCT04580147	P2	unknown	Retinal Detachment With Multiple Breaks, Unspecified Eye	150	—
KALAHARI	NCT04527107	P2	completed	Diabetes Mellitus	135	—
ENVISION	NCT05275205	P2	completed	Neovascular Age-related Macular Degeneration	51	—
INFINITY	NCT04418427	P2	completed	Diabetic Macular Edema	36	—
AFEMA	NCT03279289	P2	completed	Metastatic Colorectal Cancer	170	—
INTEGRAL	NCT05063734	P2	terminated	Diabetes Mellitus	16	—
DRAW-2	NCT04588948	P2	withdrawn	Diabetic Macular Edema	0	PMID 22836776
TOFU	NCT04200248	P2	completed	Exudative Age-related Macular Degeneration	94	—
CANDELA	NCT04126317	P2	completed	Neovascular (Wet) Age-Related Macular Degeneration	106	—
ARRT	NCT03085784	P2	unknown	Radiation Retinopathy	40	PMID 11158813
PHTHALO-205	NCT04331730	P2	completed	Neovascular Age-related Macular Degeneration	107	—
FOLFA	NCT02384759	P2	completed	Colorectal Neoplasms	117	PMID 38672597
ALTISSIMO	NCT03953079	P2	completed	Neovascular Age-Related Macular Degeneration	56	—
PERMAD	NCT02331927	P2	unknown	Metastatic Colorectal Cancer	150	—
ZEBRA	NCT03423823	P2	completed	Wet Macular Degeneration	62	—
RIA	NCT02340949	P2	completed	Rectal Cancer	180	PMID 31465088
Zaltrap	NCT02486484	P2	unknown	Neovascularization	100	PMID 27030277
PULSAR	NCT02173990	P2	terminated	Metastatic Colorectal Cancer	40	—
ALINEA	NCT02556229	P2	completed	Inflammatory Choroidal Neovascularization	20	PMID 35822428
INTUITION	NCT02257502	P2	completed	Idiopathic Choroidal Neovascularization	20	PMID 34620799
RECOVERY	NCT02863354	P2	completed	Proliferative Diabetic Retinopathy	43	PMID 31917731
DECO	NCT03452527	P2	terminated	Choroidal Neovascularization	15	—
MINOAS	NCT02624726	P2	unknown	Metastatic Colorectal Cancer	31	PMID 31203498
PRO-CON	NCT02462889	P2	completed	Age-Related Macular Degeneration	128	PMID 33734306
POLAF	NCT02970916	P2	completed	Metastatic Colorectal Cancer	100	—
EyNeP	NCT02537054	P2	completed	Pseudoxanthoma Elasticum	15	—
ASTRID	NCT02573038	P2	withdrawn	Choroidal Neovascularization in Angioid Streaks	0	—
TYBEE	NCT03126786	P2	completed	Diabetic Macular Edema	71	—
AMOUR	NCT02661711	P2	completed	Macular Oedema	30	PMID 32041720
ONYX	NCT02713204	P2	completed	Neovascular Age-Related Macular Degeneration	365	—
AMALTHEA	NCT02129257	P2	completed	Metastatic Colorectal Cancer	73	—
RUBY	NCT02712008	P2	completed	Diabetic Macular Edema	302	—
ELYSIAN	NCT02630277	P2	unknown	Proliferative Diabetic Retinopathy	30	—
CAPELLA	NCT02418754	P2	terminated	Neovascular Age-Related Macular Degeneration	505	—
AUSCOR	NCT03264274	P2	withdrawn	Colorectal Cancer	0	—
VAPOR1	NCT02401945	P2	completed	Age-Related Macular Degeneration	16	—
Drop and Go	NCT02085005	P2	withdrawn	Colorectal Cancer Metastatic	0	—
VELVET	NCT01802684	P2	completed	Unresectable Metastatic Colorectal Cancer	49	—
TANZANITE	NCT02303184	P2	completed	Macular Edema	46	—
C261	NCT01669720	P2	terminated	Metastatic Colorectal Cancer	10	—
RT	NCT01749956	P2	completed	Rectal Cancer	39	—
CONTAIN	NCT01710332	P2	completed	Central Serous Chorioretinopathy	12	PMID 25595177
AFFIRM	NCT00851084	P2	completed	Colorectal Neoplasms	268	PMID 27091810
DA VINCI	NCT00789477	P2	completed	Diabetic Macular Edema	221	—
VEGF	NCT00320788	P2	completed	Macular Degeneration	159	—

Terminated and withdrawn Aflibercept trials (56)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT06398080withdrawnAn Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
NCT05126966withdrawnA Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
NCT04757636terminatedOPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
NCT03845049terminatedComparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1
NCT05961007suspendedEvaluation of IBI302 Injection in nAMD or DME
NCT04702048withdrawnEvaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye
NCT04707625terminatedVascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment
NCT04611152terminatedA Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
NCT04603937terminatedA Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
NCT05473715terminatedA Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
NCT04698850withdrawnBrolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation
NCT04919096withdrawnStudy of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration
NCT04079231withdrawnEfficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
NCT03712904terminatedStereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
NCT05063734terminatedA Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.
NCT04049266terminatedA Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
NCT04684394terminatedA Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
NCT04588948withdrawnA Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema
NCT03810313terminatedAssessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
NCT03802630terminatedAssessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
NCT03710564terminatedStudy of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
NCT03630952terminatedEfficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)
NCT03577899terminatedEfficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
NCT03059277withdrawnIntravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab
NCT03920878withdrawnCataract DME - Peri vs. Intraop
NCT03396861terminatedTreatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept
NCT02173990terminatedAflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).
NCT02797704terminatedSubconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
NCT03452527terminatedOpen-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
NCT02980874terminatedSuprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
NCT02573038withdrawnPhase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID).
NCT01889680withdrawnSafety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer
NCT02235324withdrawnZiv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer
NCT02457026withdrawnAdjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
NCT02878681withdrawn24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.
NCT01940887terminatedA Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
NCT02418754terminatedStudy of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
NCT02002377terminatedIntravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections
NCT03264274withdrawnTrial of Aflibercept Monotherapy With DCE-US in Chemorefractory Metastatic Colorectal Cancer
NCT02387957terminatedA 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
NCT01646554withdrawnEfficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
NCT02045030terminatedStudy to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
NCT02258009withdrawnSystemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
NCT02085005withdrawnCapecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer
NCT02192541terminatedGanetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
NCT01669720terminatedAdjuvant Aflibercept for Metastatic Colorectal Cancer
NCT01868360terminatedUsing Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
NCT01746875terminatedA Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes
NCT01955629terminatedStudy of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient
NCT01965041withdrawnIntravitreal Aflibercept Injections In The Treatment Of Pattern Dystrophy
NCT01941173withdrawnShort-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy
NCT01495208withdrawnOpen Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment
NCT00794417terminatedA Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
NCT00437034terminatedAflibercept for Relapsed Multiple Myeloma
NCT00509249terminatedAflibercept in Treating Patients With Myelodysplastic Syndromes
NCT00574275terminatedAflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

All Aflibercept trials (456)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT07317934	STELLAR	Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)	P3	recruiting	332	Innostellar Biotherapeutics Co.,Ltd	Jan 2026
NCT07482176	AQUARIUS	Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)	P3	recruiting	284	Adverum Biotechnologies, Inc.	Mar 2026
NCT05197270		4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration	P1/P2	recruiting	215	4D Molecular Therapeutics	Dec 2021
NCT06856577	ARTEMIS	Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration	P3	active not recruiting	311	Adverum Biotechnologies, Inc.	Feb 2025
NCT06121180		Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma	P2	recruiting	32	H. Lee Moffitt Cancer Center and Research Institute	Nov 2024
NCT06196840	VENUS	Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)	P2	active not recruiting	50	Innostellar Biotherapeutics Co.,Ltd	Jan 2024
NCT07064759	4FRONT-2	Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration	P3	recruiting	480	4D Molecular Therapeutics	Jul 2025
NCT06817343		A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)	P1	active not recruiting	12	Exegenesis Bio	Sep 2024
NCT05930561		4D-150 in Patients With Diabetic Macular Edema	P2	active not recruiting	72	4D Molecular Therapeutics	Aug 2023
NCT06398080	SPECTRUM-US	An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting	—	withdrawn	0	Regeneron Pharmaceuticals	Dec 2024
NCT07389980	PALLAS	Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial	P3	recruiting	50	Yeungnam University College of Medicine	Dec 2026
NCT04663750	TIGER	Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).	P3	recruiting	210	King's College Hospital NHS Trust	Apr 2021
NCT07449936	DME	COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME	P3	recruiting	240	EyePoint Pharmaceuticals, Inc.	Feb 2026
NCT07449923	DME	CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME	P3	recruiting	240	EyePoint Pharmaceuticals, Inc.	Feb 2026
NCT05251636	KILAUEA	Adjunct Episcleral Brachytherapy for PCV	P3	not yet recruiting	159	Salutaris Medical Devices, Inc.	Mar 2025
NCT07496567	TORRONTES	A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)	P2/P3	recruiting	960	EyeBiotech Ltd.	Apr 2026
NCT07440225	MALBEC	A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)	P2/P3	recruiting	960	EyeBiotech Ltd.	Mar 2026
NCT07205887	Super Tuscan	A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO	P2	recruiting	160	EyeBiotech Ltd.	Sep 2025
NCT06864988		4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration	P3	active not recruiting	480	4D Molecular Therapeutics	Mar 2025
NCT04519619	NVG	Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)	—	recruiting	480	Bayer	Nov 2020
NCT07118670	HERO	High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes	P4	active not recruiting	40	Edward Wood, MD	Dec 2025
NCT04932980	SPARROW	Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD	N/A	active not recruiting	80	Berner Augenklinik	May 2022
NCT07438119	DECADE	Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients	P4	not yet recruiting	114	Kun Liu	Mar 2026
NCT07489131	ALVOEYE-HD	Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema	P3	recruiting	256	Alvotech Swiss AG	Apr 2026
NCT06075147		The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema	—	active not recruiting	2,500	Bayer	Feb 2024
NCT07340372	HOME	Home Monitoring in eAMD Treatment	—	not yet recruiting	80	Association for Innovation and Biomedical Research on Light and Image	May 2026
NCT07365371	PCV	A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)	P4	not yet recruiting	174	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Jan 2026
NCT06942520	ELAAVATE	Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)	P2	recruiting	18	Sierra Eye Associates	Mar 2025
NCT05407636	ASCENT	Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD	P3	recruiting	714	AbbVie	Jan 2022
NCT06683742	wAMD	A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56	P3	active not recruiting	400	EyePoint Pharmaceuticals, Inc.	Nov 2024
NCT05769153	NOVA-1	Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)	P1/P2	active not recruiting	139	Alcon Research	Dec 2023
NCT06223958		Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration	P3	active not recruiting	344	Ocular Therapeutix, Inc.	Jan 2024
NCT07489586		A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration	P3	not yet recruiting	356	Qilu Pharmaceutical Co., Ltd.	Mar 2026
NCT06668064	wAMD	A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56	P3	active not recruiting	400	EyePoint Pharmaceuticals, Inc.	Oct 2024
NCT06556368	DAYBREAK	A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK	P3	active not recruiting	675	Kodiak Sciences Inc	Aug 2024
NCT07557121		Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration	P2	not yet recruiting	35	AiViva BioPharma, Inc.	Jul 2026
NCT06321302		A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy	P2	active not recruiting	190	Boehringer Ingelheim	May 2024
NCT06662994		High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy	P4	recruiting	15	Retina Consultants of Orange County	Jul 2025
NCT06929143		A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema	—	active not recruiting	3,000	Bayer	Apr 2025
NCT04101877	SAHLVE	The Sahlgrenska Anti-VEGF Study	P2	active not recruiting	402	Vastra Gotaland Region	Sep 2020
NCT06610747	DME HOME	Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT	N/A	recruiting	308	Zhongshan Ophthalmic Center, Sun Yat-sen University	Oct 2024
NCT06315556	UK	An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)	—	recruiting	200	Bayer	Mar 2024
NCT05972473		A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD	P3	active not recruiting	600	Innovent Biologics (Suzhou) Co. Ltd.	Sep 2023
NCT06850922	THAMES	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema	P1/P2	active not recruiting	546	Genentech, Inc.	Jun 2022
NCT05705258		A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)	—	active not recruiting	75	Bayer	Mar 2023
NCT06929507		Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients	N/A	recruiting	60	University Hospital, Alexandroupolis	Mar 2025
NCT06839339		Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD	P2	not yet recruiting	40	Beijing Anlong Biopharmaceutical Co., Ltd.	Feb 2025
NCT02298959		Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer	P1	active not recruiting	59	National Cancer Institute (NCI)	Apr 2015
NCT06495918		Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration	P3	active not recruiting	825	Ocular Therapeutix, Inc.	Nov 2024
NCT06491914	ELARA	A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)	P3	active not recruiting	1,118	Regeneron Pharmaceuticals	Jul 2024
NCT04567550	ALTITUDE®	RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)	P2	active not recruiting	139	AbbVie	Nov 2020
NCT07423429	AFLIWEST	Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration	—	not yet recruiting	100	Nantes University Hospital	Feb 2026
NCT07301775		Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery	P4	not yet recruiting	166	Ahmad Zeeshan Jamil	Jan 2026
NCT06116890		Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration	P2	active not recruiting	180	Kyowa Kirin Co., Ltd.	Jan 2024
NCT06116916		Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema	P2	active not recruiting	150	Kyowa Kirin Co., Ltd.	Jan 2024
NCT07235527		Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration	—	recruiting	54	Saglik Bilimleri Universitesi	Nov 2025
NCT05885503		Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema	P3	recruiting	316	RemeGen Co., Ltd.	Jun 2023
NCT07390253		Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration	—	active not recruiting	50	Vienna Institute for Research in Ocular Surgery	Sep 2024
NCT06683950		Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment	P4	recruiting	40	Kim's Eye Hospital	Oct 2024
NCT07434713	ELEV8	EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).	—	recruiting	50	Insel Gruppe AG, University Hospital Bern	Jul 2025
NCT06422507	PHOTONiC	A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema	P3	completed	333	Bayer	May 2024
NCT07338097		Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema	N/A	enrolling by invitation	116	CMH Multan Institute of Medical Sciences	Sep 2025
NCT05126966	Diagrid	A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration	P3	withdrawn	0	Hoffmann-La Roche	Dec 2023
NCT07526857	GLIA-MAC	Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy	—	completed	60	Federico II University	Jan 2025
NCT02645266		Mean Visual Acuity Changes Following Five Injections of Aflibercept	N/A	active not recruiting	48	McMaster University	May 2018
NCT02669953	OPHTH-010915	Aflibercept in Recurrent or Persistent CNV	—	recruiting	80	Medical University of Vienna	Dec 2015
NCT05727397		Efficacy and Safety of RC28-E Versus Aflibercept	P3	unknown	432	RemeGen Co., Ltd.	Mar 2023
NCT06879301		Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients	Early P1	not yet recruiting	60	Tanta University	Oct 2025
NCT06850571		Aflibercept and Bevacizumab for Diabetic Maculopathies	P4	recruiting	102	Al-Mustansiriyah University	Feb 2025
NCT04810585		Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer	P4	unknown	153	Yonsei University	Apr 2020
NCT06591598	DEUTERON	A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration	P4	completed	51	Bayer	Sep 2024
NCT04015180	FIREFLEYE next	Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090	P3	completed	100	Bayer	Mar 2020
NCT07105228		Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study	—	completed	290,000	Regeneron Pharmaceuticals	Jul 2025
NCT06769412	RV	A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)	—	completed	550,000	Regeneron Pharmaceuticals	Jul 2025
NCT06132035		Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration	P1	recruiting	45	Caregen Co. Ltd.	Dec 2023
NCT05850520	QUASAR	A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)	P3	completed	892	Bayer	May 2023
NCT05342857		Maximum Treatment Interval With Aflibercept T&E	—	unknown	100	Shin Kong Wu Ho-Su Memorial Hospital	Jan 2022
NCT06011798	UBX1325	Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)	P2	completed	52	Unity Biotechnology, Inc.	Aug 2023
NCT05990829		Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial	P4	unknown	64	Tianjin Medical University Eye Hospital	Oct 2023
NCT04757636	COAST	OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)	P3	terminated	998	Opthea Limited	Mar 2021
NCT03845049	TELeMAC	Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1	P3	terminated	16	Centre Hospitalier Universitaire Dijon	Jul 2019
NCT04793100	PULSOV	Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections	N/A	completed	60	Fondation Ophtalmologique Adolphe de Rothschild	Mar 2021
NCT03186326	SAMCO	Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer	P2	completed	132	Federation Francophone de Cancerologie Digestive	Apr 2018
NCT05941715	FAN	Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration	P4	completed	70	Medical University of Graz	Jul 2023
NCT03172299	PROTECT	Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma	P3	completed	57	Centre Hospitalier Universitaire de Nice	Jun 2017
NCT04469595	NEW DAY	A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)	P4	active not recruiting	300	Alimera Sciences	Aug 2020
NCT02321267		Cohort Study of the Clinical Course of Macular Diseases in Kagawa	P4	unknown	1,000	Kagawa University	Dec 2014
NCT04311606	AcTED	Anti-VEGF Therapy for Acute Thyroid Eye Disease	P2	completed	11	Massachusetts Eye and Ear Infirmary	Nov 2020
NCT06099184	VERONA	Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)	P2	completed	27	EyePoint Pharmaceuticals, Inc.	Jan 2024
NCT05155293	ALVOEYE	Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)	P3	completed	413	Alvotech Swiss AG	Jun 2022
NCT05891548	ODYSSEY	Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration	P2	completed	60	Clearside Biomedical, Inc.	May 2023
NCT04655482		Treat-and-extend Using Aflibercept for Type 3 Neovascularization	P4	unknown	30	Kim's Eye Hospital	Feb 2021
NCT04423718	PULSAR	Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye	P3	completed	1,011	Bayer	Aug 2020
NCT04708145	VOYAGE	Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial	P4	completed	41	Greater Houston Retina Research	Jun 2021
NCT06878573		Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema	—	completed	36	Augenabteilung Allgemeines Krankenhaus Linz	Nov 2023
NCT05324774		Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema	P3	unknown	346	Mabwell (Shanghai) Bioscience Co., Ltd.	Feb 2022
NCT04392479	TWICE-IRI	TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.	P3	unknown	202	Hôpital Franco-Britannique-Fondation Cognacq-Jay	Sep 2020
NCT04429503	PHOTON	Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease	P2/P3	completed	660	Regeneron Pharmaceuticals	Jun 2020
NCT06205979		Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents	Early P1	unknown	50	Sohag University	Dec 2023
NCT03941587		Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment	N/A	completed	60	Singapore National Eye Centre	Feb 2021
NCT07096713	Anti-VEGF	Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema	N/A	completed	38	Benha University	Jan 2024
NCT05989126	PFS	Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)	P3	completed	35	Regeneron Pharmaceuticals	Apr 2024
NCT05662410		Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy	P4	completed	30	Kim's Eye Hospital	Dec 2022
NCT05403749		A Study of Longer Interval of IVT IBI302 in Subjects With nAMD	P2	completed	132	Innovent Biologics (Suzhou) Co. Ltd.	Jun 2022
NCT04397601	ARBITRATION	Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer	—	unknown	220	National Cancer Institute, Naples	May 2020
NCT05961007		Evaluation of IBI302 Injection in nAMD or DME	P1/P2	suspended	234	Innovent Biologics (Suzhou) Co. Ltd.	Nov 2021
NCT05381948	DAVIO2	Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)	P2	completed	161	EyePoint Pharmaceuticals, Inc.	Jun 2022
NCT05511038	VISION-AF	A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema	P4	completed	100	Bayer	Aug 2022
NCT02081339		Cohort Study of the Clinical Course of Macular Diseases in Japanese	—	unknown	1,000	Kyoto University, Graduate School of Medicine	Mar 2014
NCT03832179	STAMP	Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification	P4	completed	16	Bay Area Retina Associates	Nov 2018
NCT04047472		Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration	P3	completed	397	Novartis Pharmaceuticals	Nov 2019
NCT03056079	COVARIANT	Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept	P4	unknown	168	Unity Health Toronto	Feb 2017
NCT04702048	PRAVA	Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye	P4	withdrawn	0	University of Rochester	Feb 2021
NCT03780361	FORESIGHT	Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT)	P4	completed	23	Hyewon Chung	May 2019
NCT03530267	ELDERLY	Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer	P2	completed	124	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Sep 2018
NCT04411693	PRECISION	Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema	P4	completed	23	The Cleveland Clinic	Apr 2020
NCT02159989		Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	P1	completed	83	National Cancer Institute (NCI)	Jun 2014
NCT04707625	VEGF	Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment	P4	terminated	17	Wake Forest University Health Sciences	Oct 2021
NCT04989699		Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration	P1	completed	21	Ocular Therapeutix, Inc.	Jul 2021
NCT04580147	PREVENT-PVR	Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair	P2	unknown	150	M. Ali Khan, MD	Oct 2020
NCT05662943		Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV	—	completed	135	Kim's Eye Hospital	Dec 2022
NCT04707027		Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept	N/A	unknown	80	Chiang Mai University	Nov 2020
NCT04527107	KALAHARI	A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema	P2	completed	135	Oxurion	Jul 2020
NCT03939767	XTEND	Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease	—	completed	1,563	Bayer	May 2019
NCT04611152	GLEAM	A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)	P3	terminated	460	Kodiak Sciences Inc	Sep 2020
NCT04603937	GLIMMER	A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)	P3	terminated	459	Kodiak Sciences Inc	Sep 2020
NCT05710471		Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E	P4	completed	30	The University of Hong Kong	Jul 2022
NCT05275205	ENVISION	Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)	P2	completed	51	Unity Biotechnology, Inc.	Mar 2022
NCT04740931	COMINO	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion	P3	completed	729	Hoffmann-La Roche	Mar 2021
NCT05473715	XPAND	A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment	P4	terminated	3	Bayer	Apr 2023
NCT04698850	BEY-RAP	Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation	P4	withdrawn	0	Faculty Hospital Kralovske Vinohrady	Jan 2021
NCT04662944	RAZORBILL	A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections	—	completed	494	Novartis Pharmaceuticals	Feb 2021
NCT03999125		Anti-VEGF Therapy Versus Dexamethasone Implant for DME	P4	unknown	150	Sudhalkar Eye Hospital	Jun 2019
NCT04418427	INFINITY	ADVM-022 Intravitreal Gene Therapy for DME	P2	completed	36	Adverum Biotechnologies, Inc.	May 2020
NCT04740905	BALATON	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion	P3	completed	553	Hoffmann-La Roche	Mar 2021
NCT04113538		Treat and Extend Analysis Trial With Aflibercept in Wet-AMD	P3	unknown	40	Michel Giunta	Jul 2019
NCT03622593	RHINE	A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema	P3	completed	951	Hoffmann-La Roche	Oct 2018
NCT03290794	IVT-AFL	Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice	—	completed	100	Bayer	Feb 2019
NCT04522167	MAGELLAN-AMD	Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration	P3	completed	434	Bioeq GmbH	Jul 2020
NCT03714308	ANDROMEDA	Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.	—	completed	554	Bayer	Jan 2019
NCT05222633		Anti-VEGF in Real-world	—	unknown	1,000	Wenbin Wei	Jan 2022
NCT04964089	DAYLIGHT	A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)	P3	completed	557	Kodiak Sciences Inc	Jun 2021
NCT05704725	CVD	A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)	P3	completed	49	Amgen	Jan 2023
NCT03279289	AFEMA	Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen	P2	completed	170	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	Oct 2017
NCT04137120	MAIA	Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice	—	completed	73	Bayer	Feb 2021
NCT04919096		Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration	P1	withdrawn	0	Clover Biopharmaceuticals AUS Pty	Apr 2022
NCT04079231	BUZZARD	Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema	P3	withdrawn	0	Novartis Pharmaceuticals	Feb 2021
NCT04058067	KINGLET	To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema	P3	completed	266	Novartis Pharmaceuticals	Aug 2019
NCT04270747		A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]	P3	completed	576	Amgen	Jun 2020
NCT04592419	BEACON	A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)	P3	completed	568	Kodiak Sciences Inc	Sep 2020
NCT04820452		A Study of IBI302 in Patients With nAMD	P2	completed	231	Innovent Biologics (Suzhou) Co. Ltd.	Apr 2021
NCT03297684		Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection	—	unknown	40	Advanced Eye Research Associates	Apr 2018
NCT03712904		Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma	P2	terminated	3	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Aug 2019
NCT05683912	ADMIRE	Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece	—	completed	100	University of Athens	Sep 2019
NCT02681783	PRaCTICAL	PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept	P4	unknown	90	Sunnybrook Health Sciences Centre	Dec 2018
NCT04524910	REALM	A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)	—	completed	28	Bayer	Jun 2021
NCT04005352	TALON	Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)	P3	completed	734	Novartis Pharmaceuticals	Sep 2019
NCT04480463	AMD	A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)	P3	completed	576	Sam Chun Dang Pharm. Co. Ltd.	Aug 2020
NCT02550002		Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen	—	completed	150	Insel Gruppe AG, University Hospital Bern	Dec 2015
NCT01652196		Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer	P2	completed	56	John Hays	Nov 2012
NCT04101721	BUTTERFLEYE	Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity	P3	completed	127	Regeneron Pharmaceuticals	Oct 2019
NCT06146309		Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein Occlusion	N/A	completed	60	Al-Azhar University	Dec 2020
NCT05587062		Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration	P3	completed	168	Cinnagen	Oct 2019
NCT05080803		Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome	—	completed	608	European School of Advanced Studies in Ophthalmology	Jun 2021
NCT03709745		Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion	P4	completed	110	St. Erik Eye Hospital	Oct 2018
NCT05063734	INTEGRAL	A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.	P2	terminated	16	Oxurion	Aug 2021
NCT03043729		mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer	P2	completed	119	AIO-Studien-gGmbH	Mar 2017
NCT05282420		Ranibizumab Versus Aflibercept for CRVO in Young Patients.	P4	unknown	40	South Valley University	Feb 2021
NCT05178745		Resection Observatory	—	completed	140	Sanofi	Sep 2016
NCT02432547	LADAMO	Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO)	P4	completed	48	University of Sydney	Jun 2017
NCT02634333		Anti-VEGF Treatment for Prevention of PDR/DME	P3	completed	399	Jaeb Center for Health Research	Jan 2016
NCT04049266	DAZZLE	A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.	P2/P3	terminated	559	Kodiak Sciences Inc	Oct 2019
NCT04450329	AMD	A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)	P3	completed	449	Samsung Bioepis Co., Ltd.	Jun 2020
NCT06330220		Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity	P4	completed	12	Seoul National University Hospital	Feb 2021
NCT04684394		A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration	P2	terminated	50	Gemini Therapeutics, Inc.	Dec 2020
NCT05324592		Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema	P1	completed	24	Mabwell (Shanghai) Bioscience Co., Ltd.	Feb 2021
NCT05345236		A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)	P3	completed	366	Qilu Pharmaceutical Co., Ltd.	Aug 2019
NCT03823287	TENAYA	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)	P3	completed	671	Hoffmann-La Roche	Feb 2019
NCT03823300	LUCERNE	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)	P3	completed	658	Hoffmann-La Roche	Mar 2019
NCT04588948	DRAW-2	A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema	P2	withdrawn	0	Stanford University	Dec 2020
NCT01782443		Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors	P2	completed	19	Dana-Farber Cancer Institute	Feb 2013
NCT04200248	TOFU	A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration	P2	completed	94	Ribomic USA Inc	Dec 2019
NCT03321513	DRCR AC	DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME	P3	completed	270	Jaeb Center for Health Research	Dec 2017
NCT03161912	AURIGA	A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease	—	completed	2,481	Bayer	Nov 2017
NCT04126317	CANDELA	Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration	P2	completed	106	Regeneron Pharmaceuticals	Nov 2019
NCT03730558	ZETA	ZETA : Prospective Observational Study	—	completed	120	Recherche clinique	Nov 2017
NCT03085784	ARRT	Intravitreal Aflibercept Injection for Radiation Retinopathy Trial	P2	unknown	40	Amy C Schefler, MD	Jul 2017
NCT03481634	KESTREL	Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema	P3	completed	566	Novartis Pharmaceuticals	Jul 2018
NCT03651011	NIRVANA	Navigated Laser In Branch Retinal Vein Occlusion Study	N/A	completed	47	Odense University Hospital	Aug 2018
NCT04331730	PHTHALO-205	A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD	P2	completed	107	Alkahest, Inc.	Jan 2020
NCT03622580	RO6867461	A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)	P3	completed	940	Hoffmann-La Roche	Sep 2018
NCT03810313	RAVEN	Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion	P3	terminated	493	Novartis Pharmaceuticals	Jul 2019
NCT03802630	RAPTOR	Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion	P3	terminated	450	Novartis Pharmaceuticals	Jul 2019
NCT03710564	MERLIN	Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections	P3	terminated	535	Novartis Pharmaceuticals	Oct 2018
NCT02384759	FOLFA	Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers	P2	completed	117	Federation Francophone de Cancerologie Digestive	May 2015
NCT04641234	BELUGA	A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).	—	completed	330	Bayer	Dec 2020
NCT03481660	KITE	A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema	P3	completed	360	Novartis Pharmaceuticals	Jul 2018
NCT03953079	ALTISSIMO	A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD	P2	completed	56	Graybug Vision	Sep 2019
NCT03630952	PANDA-2	Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)	P3	terminated	1,157	Chengdu Kanghong Biotech Co., Ltd.	Dec 2018
NCT03577899	PANDA-1	Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)	P3	terminated	1,157	Chengdu Kanghong Biotech Co., Ltd.	Sep 2018
NCT04370379		Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients	P1	completed	18	Innovent Biologics (Suzhou) Co. Ltd.	May 2020
NCT03531294		Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement	P2	completed	40	Greater Houston Retina Research	May 2018
NCT04970251		Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma	N/A	completed	5	Siriraj Hospital	Nov 2018
NCT02331927	PERMAD	PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer	P2	unknown	150	University of Ulm	Mar 2015
NCT01969708	SCORE2	Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)	P3	completed	362	The Emmes Company, LLC	Sep 2014
NCT03917472	KINGFISHER	Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema	P3	completed	517	Novartis Pharmaceuticals	Jul 2019
NCT03197480	DEAR	Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME	P4	unknown	36	Singapore National Eye Centre	Apr 2019
NCT04004208	FIREFLEYE	Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy	P3	completed	113	Bayer	Sep 2019
NCT03117634		An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy	P4	completed	54	Singapore National Eye Centre	Dec 2017
NCT03470103	AQUILA	A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America	—	completed	643	Bayer	Mar 2018
NCT02559180	SwapTwo	Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab	P4	completed	20	Rishi Singh	Oct 2015
NCT02174211	VITCLEAR	A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.	N/A	completed	59	King's College Hospital NHS Trust	Jun 2014
NCT03597815	DME-OSA	Diabetic Macular Edema - Obstructive Sleep Apnea Relationship Study	—	unknown	150	Uptown Eye Specialists	Jan 2018
NCT02850263	DRAKO	A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema	—	completed	750	Bayer	Jul 2016
NCT03059277		Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab	P4	withdrawn	0	Southeast Clinical Research Associates, LLC	Jun 2018
NCT03405376		Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion	P4	unknown	49	Yeungnam University College of Medicine	Jan 2018
NCT03022292	IAI-OCTA	The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy	P4	completed	26	University of California, Los Angeles	Mar 2017
NCT02586727		Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy	P2	completed	40	Larkin Community Hospital	Oct 2015
NCT03767738		Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe	P4	completed	65	Regeneron Pharmaceuticals	Dec 2018
NCT03920878		Cataract DME - Peri vs. Intraop	P2	withdrawn	0	Emory University	May 2020
NCT03594461	I-TRAP	Intense Treatment Regimen With Intravitreal Aflibercept Injection	P1/P2	unknown	30	Vitreous -Retina- Macula Consultants of New York	Sep 2018
NCT03423823	ZEBRA	Ziv-aflibercept Efficacy in Better Regulating AMD	P2	completed	62	Kapil Kapoor	Jul 2017
NCT03397264		A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema	P1/P2	completed	153	Opthea Limited	Jan 2018
NCT02540954		Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)	P3	completed	336	Bayer	Sep 2015
NCT02151695		Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.	P2	completed	41	Poitiers University Hospital	May 2015
NCT02403128		Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery Macroaneurysms	P1	unknown	6	Kamal Kishore, MD	May 2015
NCT02340949	RIA	Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer	P2	completed	180	Grupo Espanol Multidisciplinario del Cancer Digestivo	Jan 2015
NCT02858076	AB	Anti-VEGF vs. Prompt Vitrectomy for VH From PDR	P2/P3	completed	205	Jaeb Center for Health Research	Nov 2016
NCT01988246	PROMISE	Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery	P1/P2	completed	30	Rishi Singh	Dec 2013
NCT03396861	ACME	Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept	P1	terminated	1	Tufts Medical Center	Feb 2019
NCT04290195		Use of Ziv Aflibercept in Different Retinal Diseases	P1/P2	completed	55	Amin El Sayed Nawar	Jun 2019
NCT02788877	VIBIM	Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)	P4	unknown	48	Pusan National University Hospital	Apr 2016
NCT02486484	Zaltrap	Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection	P2	unknown	100	Rafic Hariri University Hospital	Mar 2015
NCT02495181	ATLANTIC	Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy	P4	completed	50	Association for Innovation and Biomedical Research on Light and Image	Nov 2015
NCT02821247	PERSEUS-GR	Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece	—	completed	119	Bayer	Jul 2016
NCT02924311	APOLLON	Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema	—	completed	402	Bayer	Sep 2016
NCT02689518	EAGLE	EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection	P4	completed	50	University of California, San Diego	Apr 2014
NCT02173990	PULSAR	Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).	P2	terminated	40	Centre Oscar Lambret	Jul 2014
NCT02556229	ALINEA	Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory CNV in Young Patients (ALINEA).	P2	completed	20	Hospices Civils de Lyon	Jun 2016
NCT02441907		Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema	P4	completed	16	Unity Health Toronto	Aug 2015
NCT04153253		Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage	P4	completed	34	Al Hadi Hospital	Mar 2018
NCT02818998	VIOLET	Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)	P3	completed	463	Bayer	Nov 2016
NCT02797704		Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization	P1/P2	terminated	6	Rabin Medical Center	Mar 2017
NCT02425501		Special Drug Use Investigation of EYLEA for Diabetic Macular Edema	—	completed	646	Bayer	Jan 2015
NCT03468296	TRISTAR	Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept	P4	unknown	22	Tennessee Retina	Apr 2018
NCT03766425		Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy.	Early P1	completed	64	Medical University of Lublin	Jun 2017
NCT02800642	CENTERA	Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO	P4	completed	162	Bayer	Jun 2016
NCT02718326	PANORAMA	Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)	P3	completed	402	Regeneron Pharmaceuticals	Mar 2016
NCT04075188		Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid	N/A	completed	17	Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo	Sep 2017
NCT02257502	INTUITION	Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients	P2	completed	20	Hospices Civils de Lyon	Jul 2015
NCT02289924	PERSEUS-IT	Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy	—	completed	912	Bayer	Jan 2015
NCT04087746	DME	Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)	P4	completed	400	Minia University	Jan 2017
NCT02863354	RECOVERY	Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy	P2	completed	43	Charles C Wykoff, PhD, MD	Aug 2016
NCT01756248	AMD	EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan	—	completed	3,872	Bayer	Dec 2012
NCT02581891	ARIES	Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye	P4	completed	287	Bayer	Nov 2015
NCT03452527	DECO	Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)	P2	terminated	15	Iconic Therapeutics, Inc.	Mar 2018
NCT01627249	Protocol T	Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema	P3	completed	660	Jaeb Center for Health Research	Aug 2012
NCT02279537	RAINBOW	Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD	—	completed	593	Bayer	Jan 2014
NCT02624726	MINOAS	Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment	P2	unknown	31	Hellenic Oncology Research Group	Jan 2016
NCT02462889	PRO-CON	IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD	P2	completed	128	Jeffrey S Heier	Jun 2015
NCT01579760		Intravitreal Aflibercept Injection for Radiation Retinopathy	P1	completed	9	Washington University School of Medicine	Nov 2012
NCT03639675	VENERA	Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied	P3	completed	16	Bayer	Oct 2018
NCT03411941	REALE	Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)	—	completed	116	Bayer	Feb 2018
NCT03249740	GB-102	A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration	P1	completed	32	Graybug Vision	Aug 2017
NCT02590094		Preoperative Bevacizumab and Ziv-Aflibercept Administration in PDR Subjects Undergoing PPV	N/A	completed	568	Panhandle Eye Group, LLP	Oct 2015
NCT02860858	PCV	Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)	P4	completed	50	Department of Medical Services Ministry of Public Health of Thailand	Dec 2016
NCT02970916	POLAF	Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms	P2	completed	100	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	Nov 2016
NCT01783925	PMS	Eylea Post Marketing Surveillance(PMS)	—	completed	3,206	Bayer	Apr 2014
NCT03866746	MPL	Aflibercept With and Without Micropulse Laser in Diabetic Macular Edema	P4	completed	51	Al Hadi Hospital	May 2017
NCT02980874	SAPPHIRE	Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO	P3	terminated	460	Clearside Biomedical, Inc.	Jan 2017
NCT04014556		Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema	N/A	completed	40	University of Alexandria	Apr 2016
NCT03521895	GALAXY	An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies	—	completed	1,000	Bayer	May 2018
NCT02320474	ATTRACT	Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)	P4	completed	26	Poitiers University Hospital	Nov 2014
NCT03382587	ASTERIA	Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients	—	completed	163	Bayer	Dec 2017
NCT02392364	EVADE	Variable Interval Versus Set Interval Aflibercept for DME	P4	completed	50	California Retina Consultants	Apr 2015
NCT02040220	JPMS-CRVO	Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)	—	completed	385	Bayer	Jan 2014
NCT01909791	Protocol V	Treatment for CI-DME in Eyes With Very Good VA Study	P3	completed	702	Jaeb Center for Health Research	Oct 2013
NCT03386474		Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD	P3	completed	151	Novartis Pharmaceuticals	Jan 2018
NCT02633852	EYLEA	Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema	P4	completed	48	Hadassah Medical Organization	May 2016
NCT03006081		The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy	P2	completed	38	Asan Medical Center	Apr 2016
NCT02260687		Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization	—	completed	353	Bayer	Dec 2014
NCT02537054	EyNeP	Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)	P2	completed	15	University Hospital, Bonn	Sep 2015
NCT02976012	LASERLESS	Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH	P1/P2	unknown	24	Southeast Retina Center, Georgia	Jun 2016
NCT02651168		Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study	P4	unknown	50	Unity Health Toronto	Mar 2016
NCT02573038	ASTRID	Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID).	P2	withdrawn	0	Hospices Civils de Lyon	Feb 2016
NCT01889680		Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer	P2	withdrawn	0	NSABP Foundation Inc	Nov 2014
NCT03453281		Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection	P4	completed	36	Indonesia University	Oct 2017
NCT03804099		Effect Aflibercept on Ocular Perfusion	P4	completed	20	Augenabteilung Allgemeines Krankenhaus Linz	Mar 2017
NCT03370380	PED	Aflibercept in Patients With Pigment Epithelial Detachments (PED)	—	completed	18	University Hospital Muenster	Apr 2015
NCT03126786	TYBEE	Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema	P2	completed	71	Clearside Biomedical, Inc.	Jul 2017
NCT03974425		One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab	N/A	completed	37	University of Alexandria	Apr 2016
NCT02235324		Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer	P2	withdrawn	0	University of Southern California	Mar 2015
NCT01258855		Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery	P2	completed	84	National Cancer Institute (NCI)	Jan 2011
NCT02307682	HAWK	Efficacy and Safety of RTH258 Versus Aflibercept - Study 1	P3	completed	1,775	Alcon Research	Dec 2014
NCT02297204	Endurance	The Endurance 1 Trial	P4	completed	9	Northern California Retina Vitreous Associates	Nov 2014
NCT02434328	HARRIER	Efficacy and Safety of RTH258 Versus Aflibercept - Study 2	P3	completed	1,048	Alcon Research	Jul 2015
NCT02503540	PERMEATE	Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO	P4	completed	31	Justis Ehlers	Aug 2015
NCT02457026		Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD	N/A	withdrawn	0	Duke University	Jan 2016
NCT02101918		Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery	P2	completed	22	National Cancer Institute (NCI)	Jun 2014
NCT02540369	PEGASUS	To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.	—	completed	2,150	Bayer	Dec 2015
NCT02441816	VITAL	VITAL - Individualising Therapy for Neovascular AMD With Aflibercept	P4	completed	50	Moorfields Eye Hospital NHS Foundation Trust	Nov 2014
NCT03278262	INSIGHT	The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting	—	completed	2,312	Bayer	Sep 2017
NCT01657669		Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results	P4	unknown	22	Retina Research Institute, LLC	Oct 2012
NCT02645747	RETRO CRVO	Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion	—	completed	126	Bayer	Jan 2016
NCT02305238	ALTAIR	Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration	P4	completed	288	Bayer	Dec 2014
NCT02924987	Eylea	Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema	P4	unknown	40	Maisonneuve-Rosemont Hospital	Nov 2016
NCT02811692	CODEX	Study for Collection of Aflibercept Data in Routine Practice	—	completed	425	Bayer	Sep 2016
NCT04288232		Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan	P3	completed	45	Taipei Veterans General Hospital, Taiwan	Aug 2015
NCT02130024	RIVAL	A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients	P4	completed	281	Novartis Pharmaceuticals	Apr 2014
NCT02072408		Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy	P4	completed	46	Samsung Medical Center	Feb 2014
NCT02661711	AMOUR	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study	P2	completed	30	Moorfields Eye Hospital NHS Foundation Trust	Mar 2016
NCT02363621		Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME	P2	completed	101	Arshad Khanani	Jan 2015
NCT02949024	HULK	Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema	P1/P2	completed	20	Clearside Biomedical, Inc.	Nov 2016
NCT03324542	OIVAEGFFAMDIT	Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan	—	completed	63	Changhua Christian Hospital	Apr 2017
NCT02713204	ONYX	Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection	P2	completed	365	Regeneron Pharmaceuticals	Mar 2016
NCT02878681	TIDE DME	24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.	P4	withdrawn	0	Novartis Pharmaceuticals	Sep 2016
NCT01940887	E10030	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy	P3	terminated	645	Ophthotech Corporation	May 2014
NCT02734407	Endurance3	Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema	P4	completed	9	Retina-Vitreous Associates Medical Group	Jan 2015
NCT02129257	AMALTHEA	Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer	P2	completed	73	Hellenic Cooperative Oncology Group	May 2014
NCT02381730	PCV	Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment	N/A	completed	37	Fondation Ophtalmologique Adolphe de Rothschild	Jan 2014
NCT02321241	TITAN	Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD	—	completed	236	Bayer	Feb 2016
NCT02581995	AQUA	Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.	P4	completed	560	Bayer	Nov 2015
NCT03355638		Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3	P4	completed	60	Università degli Studi di Brescia	Jan 2016
NCT02181556		Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer	P2	completed	41	Federation Francophone de Cancerologie Digestive	Oct 2014
NCT01747551		FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer	P2	completed	64	Dana-Farber Cancer Institute	Jan 2013
NCT02712008	RUBY	Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema	P2	completed	302	Regeneron Pharmaceuticals	Mar 2016
NCT02120950	PLANET	Aflibercept in Polypoidal Choroidal Vasculopathy	P4	completed	333	Bayer	May 2014
NCT03313401		Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration	—	completed	34	Ulucanlar Eye Training and Research Hospital	Jan 2017
NCT02630277	ELYSIAN	Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN	P2	unknown	30	Valley Retina Institute	Jan 2016
NCT02257632	TIDE AMD	Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration	P4	completed	41	Novartis Pharmaceuticals	Apr 2015
NCT01958918	SALT	Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD	P4	completed	712	Novartis Pharmaceuticals	Oct 2013
NCT02418754	CAPELLA	Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)	P2	terminated	505	Regeneron Pharmaceuticals	May 2015
NCT01914380	PERSEUS	Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration	—	completed	988	Bayer	Jul 2013
NCT03712670		Nutraceutical Support With Omega-3	N/A	completed	60	Università degli Studi di Brescia	Jan 2016
NCT01756261		EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan	—	completed	757	Bayer	Dec 2012
NCT02002377	SHIFT-2	Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections	P4	terminated	23	Unity Health Toronto	Apr 2014
NCT03264274	AUSCOR	Trial of Aflibercept Monotherapy With DCE-US in Chemorefractory Metastatic Colorectal Cancer	P2	withdrawn	0	Barts & The London NHS Trust	Feb 2017
NCT02387957		A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)	P2	terminated	63	Ophthotech Corporation	Apr 2016
NCT01571284		Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen	P3	completed	781	Sanofi	May 2012
NCT02299336		Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial	P4	completed	60	Greater Houston Retina Research	Nov 2014
NCT02274259		Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen	P4	completed	40	Anders Kvanta	Oct 2014
NCT02218177		Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD	—	completed	30	University Health Network, Toronto	Aug 2014
NCT02173873	ZIV	Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I	P1	unknown	100	Rafic Hariri University Hospital	Jun 2014
NCT01646554	BOS3	Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases	P2/P3	withdrawn	0	European Organisation for Research and Treatment of Cancer - EORTC	Dec 2012
NCT02204683	DRAW	Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration	P1	completed	5	University of Nebraska	Sep 2014
NCT02045030		Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer	P2	terminated	14	CR-CSSS Champlain-Charles-Le Moyne	Jan 2014
NCT02258009	TIDE DME	Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema	P4	withdrawn	0	Novartis Pharmaceuticals	Oct 2015
NCT02401945	VAPOR1	A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration	P2	completed	16	Santen Inc.	Apr 2015
NCT01843725	MOMENTUM1	Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers	P1	completed	37	Jules Bordet Institute	Sep 2013
NCT02556723		Intravitreal Injections of Ziv-aflibercept for Macular Diseases	N/A	completed	60	Retina Clinic, Sao Paulo, Brazil	Sep 2014
NCT01871376	EPIC	Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation	P4	completed	25	Gregg T. Kokame, MD	May 2013
NCT02396316	VEGA	Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients	P3	completed	54	Bayer	Apr 2015
NCT02597855		Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy	—	unknown	29	Yeungnam University College of Medicine	Sep 2015
NCT02085005	Drop and Go	Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer	P2	withdrawn	0	Sanofi	Mar 2014
NCT01870427	NEWTON	NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions	P4	completed	20	Northern California Retina Vitreous Associates	Jun 2013
NCT02296567		Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients	P2/P3	unknown	80	East Florida Eye Institute	Dec 2014
NCT01961414	RANGE	Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910	P4	unknown	45	Palmetto Retina Center, LLC	Oct 2013
NCT02541084		Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan	—	completed	72	Bayer	Aug 2015
NCT01802684	VELVET	OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer	P2	completed	49	GERCOR - Multidisciplinary Oncology Cooperative Group	May 2013
NCT04018833	SWITCH	Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema	—	completed	40	Bernardete Pessoa MD	Jan 2012
NCT01661972	X-TRAP	Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer	P1/P2	completed	63	John Strickler, M.D.	Aug 2012
NCT02772497		3 Month Outcome of Ziv-aflibercept for DME	P2/P3	completed	10	Marashi Eye Clinic	Jan 2016
NCT02585401		Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada	—	completed	99	Bayer	Feb 2016
NCT01918878	EYLEA	Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.	P4	unknown	48	Hadassah Medical Organization	Oct 2013
NCT01813773	ACT	Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study	P2/P3	completed	20	Ophthalmic Consultants of Long Island	Mar 2013
NCT02303184	TANZANITE	Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO	P2	completed	46	Clearside Biomedical, Inc.	Jan 2015
NCT02092532	RIVAL	Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)	P4	unknown	20	Southeast Retina Center, Georgia	Mar 2014
NCT01857544		Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy	P4	unknown	10	Tennessee Retina	Jun 2013
NCT01773954	ATLAS	Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration	N/A	completed	40	MidAtlantic Retina	Feb 2013
NCT02192541		Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas	P1	terminated	5	National Cancer Institute (NCI)	Dec 2014
NCT01669720	C261	Adjuvant Aflibercept for Metastatic Colorectal Cancer	P2	terminated	10	Brown University	Dec 2012
NCT01670162	ROLL	On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)	P4	unknown	30	Tennessee Retina	Aug 2012
NCT02645734		The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema	P2/P3	unknown	133	Shahid Beheshti University of Medical Sciences	—
NCT02157077	ARI2	Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration	P3	completed	90	Centre Hospitalier Intercommunal Creteil	Dec 2013
NCT01617148		Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept	P4	completed	26	Rishi Singh	Jun 2012
NCT02646670		Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema	P4	completed	20	Instituto de Olhos de Goiania	Jul 2015
NCT01805297		Aflibercept Injection for Proliferative Diabetic Retinopathy	P2	completed	12	University of Oklahoma	Mar 2013
NCT01997164	IVT	Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)	P1	completed	20	Regeneron Pharmaceuticals	Nov 2014
NCT02641457		Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis	P3	completed	2	Instituto de Olhos de Goiania	Mar 2014
NCT01868360		Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea	P1	terminated	2	Balamurali Ambati	Jun 2013
NCT01711879		Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma	N/A	completed	7	University of Colorado, Denver	Jan 2013
NCT01746875		A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes	N/A	terminated	9	Norwegian University of Science and Technology	Feb 2014
NCT01749956	RT	5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer	P2	completed	39	SCRI Development Innovations, LLC	Jan 2013
NCT01722656	EVEN	Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment	P4	completed	40	Southern California Desert Retina Consultants, MC	Nov 2012
NCT01722045	RE-VIEW	Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)	P4	completed	154	Regeneron Pharmaceuticals	Nov 2012
NCT01950741	VAULT	Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy	P4	completed	48	Pusan National University Hospital	Sep 2013
NCT01882868		A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan	P2	completed	62	Sanofi	Jul 2013
NCT01661270	AFLAME	A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy	P3	completed	332	Sanofi	Jul 2012
NCT02291887		Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept	—	completed	13	Associated Retinal Consultants, Michigan	Dec 2014
NCT01896284	MACBETH	Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor	P4	completed	46	Barcelona Macula Foundation	Jul 2013
NCT01670721	AFEQT	Colorectal Cancer Metastatic	P3	completed	175	Sanofi	Aug 2012
NCT01971190		Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy	P2	completed	43	Asan Medical Center	Oct 2013
NCT01955629	AMOR	Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient	P1/P2	terminated	4	Sanofi	Dec 2013
NCT01824225		Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration	P4	completed	100	Nihon University	Mar 2013
NCT01783886	VIVID EAST	Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement	P3	completed	381	Bayer	Feb 2013
NCT01578720	IAI	Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome	P1	completed	5	Retina Research Institute, LLC	Jun 2012
NCT01930552		A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies	P1	completed	20	Sanofi	Sep 2013
NCT02033018	AflibxMyopia	Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization	P4	unknown	20	Instituto de Olhos de Goiania	Oct 2013
NCT01965041	AVA	Intravitreal Aflibercept Injections In The Treatment Of Pattern Dystrophy	N/A	withdrawn	0	Manhattan Eye, Ear & Throat Hospital	Oct 2013
NCT01688960		Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies	P1	completed	48	Regeneron Pharmaceuticals	Oct 2012
NCT01363440	VISTA DME	Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema	P3	completed	466	Regeneron Pharmaceuticals	May 2011
NCT01724554	ANDROID	Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion	P1/P2	completed	24	Ophthalmic Consultants of Boston	Nov 2012
NCT01543568	TURF	Study for Recalcitrant Age Related Macular Degeneration	P4	completed	46	David M. Brown, M.D.	Feb 2012
NCT02000102		Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab	—	completed	14	Stanford University	Sep 2013
NCT01796964		Efficacy and Safety Study of ESBA1008 Versus EYLEA®	P2	completed	173	Alcon Research	Mar 2013
NCT01790893	HANDLE	Treatment for Presumed Ocular Histoplasmosis	P1/P2	unknown	40	John Kitchens, MD	Mar 2013
NCT01482910		VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)	P3	completed	304	Bayer	Dec 2011
NCT02309281		Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab	P4	completed	33	Vista Klinik	May 2013
NCT01526070		Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration	—	completed	142	Stanford University	Jan 2012
NCT01926977		Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration	P1/P2	completed	100	Arshad Khanani	Sep 2013
NCT02118831		Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF	P1/P2	completed	56	California Retina Consultants	Mar 2012
NCT00407485		VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium	P2	completed	22	National Cancer Institute (NCI)	Nov 2006
NCT01521559	VIBRANT	Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)	P3	completed	183	Regeneron Pharmaceuticals	Apr 2012
NCT01941173		Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy	N/A	withdrawn	0	City of Hope Medical Center	Jan 2014
NCT00650923		Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma	P1	completed	61	National Cancer Institute (NCI)	Jul 2008
NCT00964795	AMD	Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)	P3	completed	323	Regeneron Pharmaceuticals	Dec 2009
NCT00390234		Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma	P2	completed	63	National Cancer Institute (NCI)	Sep 2006
NCT01710332	CONTAIN	The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy	P2	completed	12	Wills Eye	Oct 2012
NCT00462826		VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer	P2	completed	49	National Cancer Institute (NCI)	Nov 2007
NCT00729157		Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy	P2	completed	41	National Cancer Institute (NCI)	Aug 2008
NCT00436501		VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	P1/P2	completed	58	National Cancer Institute (NCI)	Jan 2007
NCT01495208	FVPED	Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment	P4	withdrawn	0	Vitreous -Retina- Macula Consultants of New York	Dec 2011
NCT00369590		VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide	P2	completed	58	National Cancer Institute (NCI)	Aug 2006
NCT01714115		Use of Eylea for the Treatment of an Optic Nerve Hemangioma	—	no longer available	0	Vitreous -Retina- Macula Consultants of New York	—
NCT00828139		S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer	P2	completed	189	National Cancer Institute (NCI)	May 2009
NCT00407654		VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer	P2	completed	75	National Cancer Institute (NCI)	Oct 2006
NCT00545246		A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients	P1	completed	12	Sanofi	Oct 2007
NCT00921661		Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer	P1	completed	16	Sanofi	Jun 2009
NCT00561470	VELOUR	Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen	P3	completed	1,226	Sanofi	Nov 2007
NCT00519285	VENICE	Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer	P3	completed	1,224	Sanofi	Aug 2007
NCT01012973	GALILEO	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)	P3	completed	177	Bayer	Oct 2009
NCT00851084	AFFIRM	Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer	P2	completed	268	Sanofi	Feb 2009
NCT01148615		A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors	P1	completed	20	Sanofi	Jul 2010
NCT00644124	R-CHOP	Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma	P1	completed	25	Sanofi	Mar 2008
NCT00532155	VITAL	A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer	P3	completed	913	Sanofi	Sep 2007
NCT00637377	VIEW 2	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)	P3	completed	1,240	Bayer	Apr 2008
NCT00509795	VIEW1	Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)	P3	completed	1,217	Regeneron Pharmaceuticals	Aug 2007
NCT00794417		A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma	P1/P2	terminated	60	Regeneron Pharmaceuticals	Nov 2008
NCT00437034		Aflibercept for Relapsed Multiple Myeloma	P2	terminated	6	National Cancer Institute (NCI)	Jan 2007
NCT00450255		VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery	P2	completed	41	National Cancer Institute (NCI)	Jun 2007
NCT00479076		A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients	P1	completed	22	Sanofi	Mar 2007
NCT00369655		VEGF Trap in Treating Patients With Metastatic Breast Cancer	P2	completed	21	National Cancer Institute (NCI)	Jan 2007
NCT00509249		Aflibercept in Treating Patients With Myelodysplastic Syndromes	P2	terminated	18	National Cancer Institute (NCI)	Sep 2007
NCT00876044	QUTIE	A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients	P1	completed	88	Sanofi	Apr 2009
NCT00574275	VANILLA	Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer	P3	terminated	546	Sanofi	Dec 2007
NCT00789477	DA VINCI	DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact	P2	completed	221	Regeneron Pharmaceuticals	Dec 2008
NCT00327171		Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer	P2	completed	218	Sanofi	May 2006
NCT00327444		Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites	P2/P3	completed	58	Sanofi	Jul 2006
NCT00396591		AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites	P2	completed	16	Sanofi	Oct 2006
NCT00320788	VEGF	Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)	P2	completed	159	Regeneron Pharmaceuticals	Apr 2006
NCT00284141		Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma	P2	completed	98	Sanofi	Jan 2006
NCT00622414		Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors	P1	completed	27	National Cancer Institute (NCI)	Apr 2008
NCT00082823		Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma	P1	completed	25	Regeneron Pharmaceuticals	Jan 2004
NCT00083213		Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma	P1	completed	25	Regeneron Pharmaceuticals	Jan 2004
NCT00045266		VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma	P1	completed	0	Regeneron Pharmaceuticals	Apr 2002
NCT00036946		VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma	P1	completed	0	Regeneron Pharmaceuticals	Nov 2001

Aflibercept clinical trials: frequently asked questions

How many Aflibercept clinical trials are there?: 456 Aflibercept clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 28 are actively recruiting participants. 286 are marked completed.
Are Aflibercept clinical trials recruiting in 2026?: Yes — 28 Aflibercept trials are actively recruiting in 2026, with 382 U.S. sites across 38 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Aflibercept being studied for?: Aflibercept is being studied for Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Macular Degeneration, Wet Macular Degeneration, Age Related Macular Degeneration and 301 more. The trials are grouped by indication on this page.
What phase is Aflibercept in?: Aflibercept clinical trials span 93 Phase 4, 99 Phase 3, 103 Phase 2, 33 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Aflibercept clinical trials?: The lead sponsor across the most Aflibercept trials is Bayer, with 217 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Afliberceptas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Aflibercept overview Aflibercept evidence & publications